Since January 2020 Elsevier has created a COVID - 19 resource centre with free information in English and Mandarin on the novel coronavirus COVID - 19 . The COVID - 19 resource centre is hosted on Elsevier Connect , the company ' s public news and information website . Elsevier hereby grants permission to make all its COVID - 19 - related research that is available on the COVID - 19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories , such as the WHO COVID database with rights for unrestricted research re - use and analyses in any form or by any means with acknowledgement of the original source . These permissions are granted for free by Elsevier for as long as the COVID - 19 resource centre remains active . Journal Pre - proof SARS - CoV - 2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract Yixuan J . Hou , Kenichi Okuda , Caitlin E . Edwards , David R . Martinez , Takanori Asakura , Kenneth H . Dinnon , III , Takafumi Kato , Rhianna E . Lee , Boyd L . Yount , Teresa M . Mascenik , Gang Chen , Kenneth N . Olivier , Andrew Ghio , Longping V . Tse , Sarah R . Leist , Lisa E . Gralinski , Alexandra Schäfer , Hong Dang , Rodney Gilmore , Satoko Nakano , Ling Sun , M . Leslie Fulcher , Alessandra Livraghi - Butrico , Nathan I . Nicely , Mark Cameron , Cheryl Cameron , David J . Kelvin , Aravinda de Silva , David M . Margolis , Alena Markmann , Luther Bartelt , Ross Zumwalt , Fernando J . Martinez , Steven P . Salvatore , Alain Borczuk , Purushothama R . Tata , Vishwaraj Sontake , Adam Kimple , Ilona Jaspers , Wanda K . O’Neal , Scott H . Randell , Richard C . Boucher , Ralph S . Baric PII : S0092 - 8674 ( 20 ) 30675 - 9 DOI : https : / / doi . org / 10 . 1016 / j . cell . 2020 . 05 . 042 Reference : CELL 11447 To appear in : Cell Received Date : 24 April 2020 Revised Date : 11 May 2020 Accepted Date : 20 May 2020 Please cite this article as : Hou , Y . J . , Okuda , K . , Edwards , C . E . , Martinez , D . R . , Asakura , T . , Dinnon III . , K . H . , Kato , T . , Lee , R . E . , Yount , B . L . , Mascenik , T . M . , Chen , G . , Olivier , K . N . , Ghio , A . , Tse , L . V . , Leist , S . R . , Gralinski , L . E . , Schäfer , A . , Dang , H . , Gilmore , R . , Nakano , S . , Sun , L . , Fulcher , M . L . , Livraghi - Butrico , A . , Nicely , N . I . , Cameron , M . , Cameron , C . , Kelvin , D . J . , de Silva , A . , Margolis , D . M . , Markmann , A . , Bartelt , L . , Zumwalt , R . , Martinez , F . J . , Salvatore , S . P . , Borczuk , A . , Tata , P . R . , Sontake , V . , Kimple , A . , Jaspers , I . , O’Neal , W . K . , Randell , S . H . , Boucher , R . C . , Baric , R . S . , SARS - CoV - 2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , Cell ( 2020 ) , doi : https : / / doi . org / 10 . 1016 / j . cell . 2020 . 05 . 042 . This is a PDF file of an article that has undergone enhancements after acceptance , such as the addition of a cover page and metadata , and formatting for readability , but it is not yet the definitive version of record . This version will undergo additional copyediting , typesetting and review before it is published in its final form , but we are providing this version to give early visibility of the article . Please note that , during the production process , errors may be discovered which could affect the content , and all legal disclaimers that apply to the journal pertain . © 2020 Elsevier Inc . I n f e c t i v i t y SARS - CoV - 2 cDNA Clone nLuc Antibody concentration % N e u t r a li z a t i o n 50 % GFP Bronchi Nose Bronchiolar A l v e o li Type 1 Type 2 A C E 2 e x p r e ss i o n Ciliated cells Type 2 Type 1 Alveoli Airway epithelium SARS - CoV - 2 - nLuc Neutralization COVID - 19 human sera SARS human sera SARS - CoV - nLuc Viral aspiration Lung infection 1 SARS - CoV - 2 Reverse Genetics Reveals a Variable Infection Gradient in the 1 Respiratory Tract 2 Yixuan J . Hou 1 , 19 , Kenichi Okuda 3 , 19 , Caitlin E . Edwards 1 , 19 , David R . Martinez 1 , 19 , 3 Takanori Asakura 3 , Kenneth H . Dinnon III 2 , Takafumi Kato 3 , Rhianna E . Lee 3 , Boyd L . 4 Yount 1 , Teresa M . Mascenik 3 , Gang Chen 3 , Kenneth N . Olivier 16 , Andrew Ghio 17 , 5 Longping V . Tse 1 , Sarah R . Leist 1 , Lisa E . Gralinski 1 , Alexandra Schäfer 1 , Hong Dang 3 , 6 Rodney Gilmore 3 , Satoko Nakano 3 , Ling Sun 3 , M . Leslie Fulcher 3 , Alessandra Livraghi - 7 Butrico 3 , Nathan I . Nicely 4 , Mark Cameron 11 , Cheryl Cameron 12 , David J . Kelvin 10 , 18 , 8 Aravinda de Silva 2 , David M . Margolis 2 , 5 , 6 , Alena Markmann 5 , Luther Bartelt 5 , Ross 9 Zumwalt 13 , Fernando J . Martinez 14 , Steven P . Salvatore 15 , Alain Borczuk 15 , 10 Purushothama R . Tata 9 , Vishwaraj Sontake 9 , Adam Kimple 7 , Ilona Jaspers 8 , Wanda K . 11 O’Neal 3 , Scott H . Randell 3 , Richard C . Boucher 3 * , Ralph S . Baric 1 , 2 , 20 * 12 13 1 Department of Epidemiology , University of North Carolina at Chapel Hill , Chapel Hill , 14 NC , USA 15 2 Department of Microbiology and Immunology , University of North Carolina at Chapel 16 Hill , Chapel Hill , NC , USA 17 3 Marsico Lung Institute , University of North Carolina at Chapel Hill , Chapel Hill , NC , 18 USA 19 4 Protein Expression and Purification Core , University of North Carolina at Chapel Hill , 20 Chapel Hill , NC , USA 21 5 Department of Medicine , University of North Carolina at Chapel Hill , Chapel Hill , NC , 22 USA 23 6 HIV Cure Center , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA 24 7 Department of Otolaryngology , University of North Carolina at Chapel Hill , Chapel Hill , 25 NC , USA 26 8 Department of Pediatrics , University of North Carolina at Chapel Hill , Chapel Hill , NC , 27 USA 28 9 Department of Cell Biology , Regeneration Next Initiative , Duke University Medical 29 Center , Durham , NC , USA 30 10 Department of Microbiology and Immunology , Canadian Center for Vaccinology , 31 Dalhousie University , Halifax , NS , Canada 32 11 Department of Population and Quantitative Health Science , Case Western Reserve 33 University , Cleveland , OH , USA 34 12 Department of Nutrition , Case Western Reserve University , Cleveland , OH , USA 35 13 Department of Pathology , University of New Mexico , Albuquerque , NM , USA 36 14 Division of Pulmonary and Critical Care Medicine , Joan & Sanford I . Weill Medical 37 College of Cornell University , New York , NY , USA 38 15 Department of Pathology , Joan & Sanford I . Weill Medical College of Cornell 39 University , New York , NY , USA 40 2 16 Laboratory of Chronic Airway Infection , Pulmonary Branch , National Heart , Lung , and 41 Blood Institute , National Institutes of Health , Bethesda , MD , USA 42 17 National Health and Environmental Effects Research Laboratory , Environmental 43 Protection Agency , Chapel Hill , NC , USA 44 18 Laboratory of Immunology , Shantou University Medical College , Shantou , 45 Guangdong , China 46 19 These authors contributed equally . 47 20 Lead contact 48 49 * Correspondence : richard _ boucher @ med . unc . edu ( R . C . B . ) , rbaric @ email . unc . edu 50 ( R . S . B . ) 51 3 Summary 52 The mode of acquisition and causes for the variable clinical spectrum of COVID - 53 19 remain unknown . We utilized a reverse genetics system to generate a GFP reporter 54 virus to explore SARS - CoV - 2 pathogenesis and a luciferase reporter virus to 55 demonstrate sera collected from SARS and COVID - 19 patients exhibited limited cross - 56 CoV neutralization . High - sensitivity RNA in situ mapping revealed the highest ACE2 57 expression in the nose with decreasing expression throughout the lower respiratory tract , 58 paralleled by a striking gradient of SARS - CoV - 2 infection in proximal ( high ) vs distal 59 ( low ) pulmonary epithelial cultures . COVID - 19 autopsied lung studies identified focal 60 disease and , congruent with culture data , SARS - CoV - 2 - infected ciliated and type 2 61 pneumocyte cells in airway and alveolar regions , respectively . These findings highlight 62 the nasal susceptibility to SARS - CoV - 2 with likely subsequent aspiration - mediated virus 63 seeding to the lung in SARS - CoV - 2 pathogenesis . These reagents provide a foundation 64 for investigations into virus - host interactions in protective immunity , host susceptibility , 65 and virus pathogenesis . 66 67 Introduction 68 Severe acute respiratory syndrome coronavirus - 2 ( SARS - CoV - 2 ) has been 69 identified as the causative agent of the ongoing pandemic Coronavirus Disease 2019 70 ( COVID - 19 ) ( Gorbalenya et al . , 2020 ) . SARS - CoV - 2 emerged in Wuhan , China , in 71 December 2019 , and rapidly spread to more than 175 countries within three months 72 ( Huang et al . , 2020 ; Zhu et al . , 2020 ) . As of May 18 , 2020 , about 4 . 7 million confirmed 73 cases and > 316 , 000 deaths have been reported worldwide . The absence of approved 74 4 vaccines and only a single emergency - use FDA - approved therapeutic against SARS - 75 CoV - 2 hinders pandemic control . 76 The genome of SARS - CoV - 2 is a ~ 30kb RNA predicted to encode 16 non - 77 structural proteins ( nsp1 - 16 ) , four structural proteins ( spike , membrane , envelope , and 78 nucleocapsid ) , and eight accessory proteins ( 3a , 3b , 6 , 7a , 7b , 8b , 9b and 14 ) ( Wu et al . , 79 2020a ) , expressed from genome length or subgenomic mRNAs . The spike ( S ) 80 glycoprotein mediates viral entry via binding to the human angiotensin - converting 81 enzyme ( ACE ) - 2 ( Hoffmann et al . , 2020 ; Walls et al . , 2020 ; Yan et al . , 2020 ) , followed by 82 proteolytic processing by TMPRSS2 , furin , and perhaps other lung proteases , which 83 trigger fusion of viral and cellular membranes . Spike glycoprotein is also the main target 84 of host neutralizing antibodies ( nAbs ) ( Hoffmann et al . , 2020 ) . 85 SARS - CoV - 2 infection primarily targets the respiratory tract . A fraction of SARS - 86 CoV - 2 infections manifest as bilateral lower - zone pneumonias and diffuse alveolar 87 damage ( DAD ) that may progress to acute respiratory distress syndrome ( ARDS ) , 88 especially in the aged and individuals with co - morbidities ( Carsana et al . , 2020 ; Guan et 89 al . , 2020 ) . In comparison to MERS - CoV and SARS - CoV 2003 infections , clinical 90 symptoms of COVID - 19 are broader and more variable ( Huang et al . , 2020 ; Pan et al . , 91 2020a ; Wu and McGoogan , 2020 ; Zhu et al . , 2020 ) . Differences in transmissibility and 92 viral shedding suggest the in vivo replication sites and / or replication efficiency of SARS - 93 CoV - 2 differ significantly from SARS - CoV ( Pan et al . , 2020b ; Wölfel et al . , 2020 ; Zou et 94 al . , 2020 ) . 95 A wealth of scRNAseq data have been mobilized to describe the expression of 96 ACE2 and TMPRSS2 with emphasis on the human respiratory tract ( Aguiar et al . , 2020 ; 97 5 Sajuthi et al . , 2020 ; Sungnak et al . , 2020 ) . However , complementary techniques are 98 required to describe the organ - level architecture of receptor expression , improve on the 99 sensitivity of scRNA for low expression genes , e . g . , ACE2 , and to describe the function 100 of ACE2 , i . e . , mediate infectivity . Accordingly , a combination of RNA in situ ( ISH ) 101 hybridization techniques , a novel set of SARS - CoV - 2 reporter viruses produced by 102 reverse genetics , and primary cultures from all affected regions of the respiratory tract 103 was assembled for our investigations . 104 The reverse genetics systems were utilized to test for protection / durability of 105 protection afforded by convalescent serum and / or SARS - CoV - 2 - specific monoclonal 106 antibodies ( mAbs ) and antigenicity relationships between SARS - CoV and SARS - CoV - 2 107 after natural human infections . These tools were also utilized to contrast two non - 108 exclusive hypotheses that may account for key aspects of SARs - CoV - 2 transmission 109 and pathogenesis : 1 ) transmission is mediated by airborne microparticles directly 110 infecting the lung ( Morawska and Cao , 2020 ; Wilson et al . , 2020 ) ; or 2 ) the nose is the 111 initial site of infection , followed by aspiration of the viral inoculum from the oropharynx 112 into the lung ( Dickson et al . , 2016 ; Wölfel et al . , 2020 ) . Accordingly , we characterized 113 the ACE2 and TMPRSS2 expression levels in the nose and lung and in parallel the 114 SARS - CoV - 2 infection of human nasal , bronchial , bronchiolar , and alveolar epithelial 115 cultures . These findings were compared with virus distributions and tropisms in lungs 116 from lethal COVID - 19 cases . 117 118 Results 119 Recombinant viruses replicate similarly to the SARS - CoV - 2 clinical isolate in vitro . 120 6 A full - length infectious cDNA clone of a US SARS - CoV - 2 clinical isolate WA1 121 was generated by cloning seven genomic fragments separately into vector plasmids 122 ( Figure 1A ) . Additionally , two reporter viruses were constructed by replacing a 276 bp - 123 region in the ORF7 with a green fluorescent protein ( GFP ) or a GFP - fused 124 nanoluciferase ( nLuc ) gene ( Figure 1A ) . After assembly into full - length cDNA , full - length 125 RNA was electroporated into Vero - E6 cells ( Scobey et al . , 2013 ; Yount et al . , 2003 ) . 126 After recovering the wild - type ( WT ) , icSARS - CoV - 2 - GFP , and icSARS - CoV - 2 - nLuc - 127 GFP recombinant viruses , viral replication was confirmed by the presence of sub - 128 genomic length leader - containing RNA transcripts 20 hours post - electroporation ( Figure 129 S1 ) . All three recombinant viruses replicated ( Figure S1 ) , generated similar plaques in 130 Vero E6 cells and could be passaged serially in the cell culture without exogenous 131 trypsin ( Figure 1B ) . Cytopathic effect ( CPE ) was defined by cell rounding and 132 detachment from monolayers . GFP signals were evident in cells two days post - 133 transfection with RNA transcripts from both indicator viruses ( Figure 1C ) . 134 To distinguish our recombinant viruses from the circulating SARS - CoV - 2 strains , 135 we introduced a silent mutation ( T15102A ) into a conserved region in nsp12 to ablate 136 an endogenous SacI site in the molecular clone ( Figure S1 ) . We confirmed the 137 presence of this mutation in all three recombinant viruses but not in the clinical SARS - 138 CoV - 2 isolate by Sanger sequencing and PCR amplification followed by SacI digestion 139 ( Figures 1D and 1E ) . To evaluate viral RNA synthesis , Northern blot analyses were 140 performed that showed that the number of sgRNA bands was equivalent in the 141 recombinant and clinical isolates , confirming the presence of 8 principle subgenomic 142 mRNAs during infection ( Figure 1F ) . As expected , the molecular weights of sgRNA 2 to 143 7 7 in the two reporter viral samples were higher than those in the clinical isolate and WT 144 samples , reflecting the insertion of the 720 bp GFP gene or the 1 , 233 bp nLuc - GFP 145 gene into the 366 bp - ORF7 genetic location . These data also demonstrated that ORF7 146 was not essential for in vitro replication of SARS - CoV - 2 . 147 Next , we evaluated one - step ( MOI = 5 ) and multi - step ( MOI = 0 . 05 ) growth 148 curves of the three recombinant viruses in Vero E6 cells in comparison to the clinical 149 isolate WA1 strain . The titer of all SARS - CoV - 2 increased and plateaued to mid 10 6 150 PFU / mL within 12 - 18h in the one - step curve and within 36 - 48h in the multi - step curve 151 ( Figures 2A and 2B ) . In contrast to other reported indicator viruses ( Thao et al . , 2020 ) , 152 the three recombinant viruses replicated to titers equivalent to the clinical isolate . 153 154 Serine Proteases TMPRSS2 and Furin , but not Exogenous Trypsin , Enhance the 155 Replication of SARS - CoV - 2 . 156 Host proteases , including cell surface and intracellular proteases , play an 157 essential role in CoV infection by processing the S protein to trigger membrane fusion 158 ( Izaguirre , 2019 ; Matsuyama et al . , 2010 ; Matsuyama et al . , 2005 ; Menachery et al . , 159 2020 ; Millet and Whittaker , 2014 ; Wicht et al . , 2014 ) . Therefore , we evaluated the multi - 160 step replication ( MOI = 0 . 03 ) of the icSARS - CoV - 2 - GFP in the presence of selected 161 proteases via fluorescent microscopy and measurements of viral titer . 162 Vero cells were infected with the icSARS - CoV - 2 - GFP reporter virus in the 163 presence of 0 , 1 , or 5 µg / mL of trypsin . Unlike some coronaviruses ( CoVs ) ( Menachery 164 et al . , 2020 ; Wicht et al . , 2014 ) , trypsin did not trigger syncytium formation and at 165 24 / 48h , a slightly higher percentage of trypsin - exposed cells expressed GFP signals 166 8 and CPE as compared with controls ( Figures 2C and S2 ) . Trypsin also resulted in 167 slightly lower virus titers than controls ( Figure 2D ) , suggesting that trypsin impairs the 168 stability of viral particles in supernatants . 169 SARS - CoV - 2 S protein exhibits a novel 4 amino acid furin - cleavage site “RRAR” 170 at the junction between S1 and S2 subunits ( Andersen et al . , 2020 ; Coutard et al . , 171 2020 ) . We observed increased icSARS - CoV - 2 - GFP expression in the furin - 172 overexpressing vs WT cells at 24h ( Figure 2E ) , correlating with one log 10 higher 173 infectious titers compared to WT Vero cells at early times after infection ( Figure 2F ) . 174 Moreover , extensive CPE was noted in furin cells vs parental Vero cell cultures ( Figure 175 S2 ) . In contrast , enhanced expression of TMPRSS2 in LLC - MK cells resulted in higher 176 levels of GFP expression and higher icSARS - CoV - 2 - GFP titers ( Figures 2G and 2H ) . 177 These data suggest that serine proteases like furin and TMPRSS2 enhance the 178 replication efficiency / cytopathology of SARS - CoV - 2 in vitro . 179 180 The neutralization sensitivity of SARS - CoV - 2 nLuc virus to potent SARS and 181 MERS monoclonal antibodies and polyclonal sera 182 Three neutralization assays were developed utilizing luciferase reporter CoVs , 183 including SARS - CoV , MERS - CoV , and SARS - CoV - 2 ( Figure 3A - H ) . Previous studies 184 have identified remarkably potent SARS and MERS nAbs that target receptor binding 185 domains and exhibit strong neutralizing activities in vitro and in vivo ( Ying et al . , 2015 ; 186 Yu et al . , 2015 ; Zhu et al . , 2007 ) . We utilized three highly cross - reactive nAb against 187 SARS - CoV ( S230 , S230 . 15 , and S227 . 9 ) , two nAb against MERS - CoV ( MERS - 27 and 188 m336 ) , and one broadly cross - reactive nAb against Dengue virus ( EDE1 - C10 ) . We also 189 9 tested a pooled mouse serum sample collected from BALB / c mice vaccinated and 190 boosted with a Venezuelan equine encephalitis virus viral replicon particle ( VRP - SARS - 191 COV - 2 - S ) encoding the SARS - CoV - 2 S gene . The boost was performed three weeks 192 post - vaccination , and sera were collected one week before and one week after boost . 193 Both the MERS nAbs , MERS - 27 and m336 , neutralized the icMERS - CoV - nLuc 194 virus but not the 2003 SARS - CoV - nLuc or 2019 SARS - CoV - 2 - nLuc - GFP recombinant 195 viruses . Similarly , the three SARS nAb , S230 , S230 . 15 and S227 . 9 exhibited potent 196 neutralization activities against icSARS - CoV - nLuc , but not icSARS - CoV - 2 - nLuc - GFP 197 ( Figures 3A , 3C and 3E ) . As a negative control , a Dengue virus nAb EDE1 - C10 did not 198 neutralize any of the three tested CoVs . Importantly , the mouse serum sample 199 neutralized 99 . 4 % of the icSARS - CoV - 2 - nLuc - GFP virus at a 1 : 2 dilution after prime , 200 and much more potent neutralization was noted after VRP - SARS - CoV - 2 - S boost 201 ( Figure 3G ) . 202 The S proteins of SARS - CoV and SARS - CoV - 2 share 75 % identity in amino acid 203 sequences . To investigate whether SARS - CoV and SARS - CoV - 2 infections elicit cross - 204 neutralizing antibodies , five serum samples from patients who survived the 2003 SARS - 205 CoV Toronto outbreak and 10 serum sample from COVID - 19 survivors were evaluated 206 using nLuc neutralization assays with the two reporter CoVs . All five 2003 SARS serum 207 samples demonstrated high neutralization titers against SARS - CoV - nLuc virus , with 208 half - maximal inhibitory dilution ( ID 50 ) activities in the range from 1 : 30 . 6 to 1 : 376 . 5 209 ( Figure 3F ) . Surprisingly , two of these serum samples , A and E , neutralized icSARS - 210 CoV - 2 - nLuc - GFP with 11 . 9 - and 8 . 1 - fold of decreases in ID 50 , respectively . In contrast , 211 10 COVID - 19 convalescent serum samples displayed variable neutralization ID 50 titers 212 10 that ranged from 61 . 67 to 782 . 70 against icSARS - CoV - 2 - nLuc - GFP but little , if any , 213 neutralization of 2003 icSARS - CoV - nLuc or icMERS - CoV - nLuc viruses at the lowest 214 dilutions tested ( Figures 3B , 3D and 3H ) . 215 216 RNA in situ hybridization localization of the SARS - CoV - 2 receptor complex in the 217 normal human upper and lower respiratory tract . 218 The sites of SARS - CoV - 2 infection in the upper airways ( nose , oropharynx ) and 219 lung ( lower airways , alveoli ) are under active investigation ( Rockx et al . , 2020 ) . 220 Accordingly , we characterized ACE2 and TMPRSS2 expression in these regions using 221 RNA in situ hybridization ( Figures 4 and S3 ) . Consistent with the low level of ACE2 222 expression reported from scRNAseq data ( Brann et al . , 2020 ; Durante et al . , 2020 ; 223 Sajuthi et al . , 2020 ) , low levels of ACE2 were detected in the respiratory epithelium 224 lining the nasal cavity ( Figure 4A ) . Scattered , low levels of ACE2 and TMPRSS2 225 expression were also observed in the squamous epithelium lining oropharyngeal 226 tonsillar tissue ( Figure S3A ) . Notably , progressively reduced levels of ACE2 expression 227 were observed in the lower airway regions , culminating in minimal levels in the alveolar 228 region . Quantitative comparisons of nasal and bronchial airway epithelia obtained as 229 brush samples simultaneously from the same subjects by qPCR revealed significantly 230 higher expression of ACE2 but not TMPRSS2 in nasal vs bronchial tissues ( Figure 4B ) . 231 In a separate qPCR study , there was a gradient of reduced ACE2 expression from 232 proximal to distal intrapulmonary regions ( Figure 4C ) . In contrast , TMPRSS2 mRNA 233 exhibited an overall higher expression level in all respiratory tract regions than ACE2 . 234 11 Previously reported scRNAseq data describing ACE2 and TMPRSS2 expression 235 in the upper and lower respiratory system have detected ACE2 in ~ 5 % of total cells 236 interrogated ( Deprez et al . , 2019 ; Sajuthi et al . , 2020 ) ( Figure 4D ) . We recently 237 developed a single - cell ( cytospin ) / RNA - ISH technique that is 5 - 10x more sensitive at 238 assigning cell type - specific expression patterns than scRNAseq ( Okuda et al . , 2020 , 239 submitted to Nat Med ) ( Figure 4E ) . This technique identified ACE2 expression in ~ 20 % 240 of interrogated cells vs ~ 5 % by scRNAseq ( Figure 4F ) . These studies identified the 241 FOXJ1 - defined ciliated cell as the most frequent cell type in nasal scrapes ( Figure S4B ) , 242 and that the percentage of ciliated cells expressing ACE2 was higher in the nose than 243 bronchi ( Figure 4G ) . ACE2 + , MUC5B + defined secretory ( “club” ) cells were less 244 frequent and expressed less ACE2 than ciliated cells in each airway region ( Figure 4H , 245 I ) . Both cell types in each region exhibited considerable variability in ACE2 expression 246 ( Figures 4H , I ) . Studies of nasal submucosal glands exhibited few / no detectable ACE2 + 247 glandular cells ( Figure S4C ) . Finally , application of this technique to freshly excised 248 distal lung digests revealed expression of ACE2 in a fraction of AT2 cells ( Figure 4Evi ) . 249 ACE2 was detected in HOPX - positive cells , which in humans can be AT1 or AT2 cells 250 ( Figure 4Evii ) ( Ota et al . , 2018 ) . 251 252 Pre - existing pulmonary disease and ACE2 / TMPRSS2 expression . 253 Suppurative muco - obstructive lung diseases , e . g . , cystic fibrosis ( CF ) and non - 254 CF bronchiectasis ( NCFB ) , are characterized by airways mucus accumulation and 255 neutrophilic inflammation and are reported to be at increased risk for severe SARS - 256 CoV - 2 infections ( Boucher , 2019 ; CDC COVID - 19 Response Team , 2020 ) . To test 257 12 whether dysregulation of ACE2 expression is a feature of CF , RNA - ISH studies were 258 performed in excised CF lungs and revealed a striking upregulation of ACE2 and 259 TMPRSS2 expression in CF airways ( Figure 5A ) . 260 To gain insight into pathways that may contribute to dysregulation of ACE2 261 expression in CF lungs , the effects of selected cytokines on ACE2 expression in large 262 airway epithelial ( LAE ) cultures were tested . IL1 β , the dominant pro - mucin secretory 263 cytokine in CF and NCFB secretions ( Chen et al . , 2019 ) , upregulated ACE2 , but not 264 TMPRSS2 ( Figure 5Bi ) . Because CF subjects experience recurrent virus - driven 265 exacerbations , the effect of IFN β on ACE2 expression was tested . ACE2 expression 266 was significantly increased , whereas TMPRSS2 expression decreased , by IFN β ( Figure 267 5Bii ) . In contrast , IL13 , a cytokine associated with Th2 - high asthma , inhibited ACE2 268 expression ( Figure 5Biii ) . 269 270 Respiratory tract region - specific SARS - CoV - 2 infectivity . 271 To test the relationship between ACE2 entry receptor expression and SARS - 272 CoV - 2 infection , we inoculated primary epithelial cultures from the nasal surface 273 epithelia ( HNE , n = 9 donors ) , large airway ( bronchi , LAE , n = 7 donors ) , lower airway 274 ( bronchiolar , SAE , n = 3 donors ) , nasal submucosal glands ( n = 2 donors ) , type II - and 275 type I - like pneumocytes ( AT2 - / AT1 - like , n = 3 donors ) , microvascular endothelial cells 276 ( MVE , n = 2 donors ) , and fibroblasts ( FB , n = 2 donors ) , and an immortalized nasal cell 277 line ( UNCNN2TS ) , with icSARS - CoV - 2 - GFP reporter virus . We observed GFP signals 278 and detected viral titers in HNE , LAE , SAE , AT2 - like and AT1 - like cell cultures ( Figure 279 6A ) . In contrast , nasal submucosal gland , UNCNN2TS , MVE , or FB cells were not 280 13 susceptible , as evidenced by no GFP signals or detectable infectious titers of progeny 281 viruses ( not shown ) . 282 We measured the relative infectivity of the SARS - CoV - 2 GFP virus in primary 283 cells based on the average peak titers and observed that infectivity exhibited the same 284 pattern as the ACE2 expression levels from the upper to lower respiratory tract ( Figure 285 6Bi - 6Biv ) . The icSARS - CoV - 2 - GFP virus replicated efficiently in HNE and LAE , with 286 peak viral titers significantly higher than the titers in SAE , AT2 - like and AT1 - like cultures 287 ( Figure 6Bv ) . Although the viral peak titers were similar , the icSARS - CoV - 2 - GFP 288 infection in HNE culture resulted in significantly higher titers than LAE at 24h , 48h and 289 96h post - infection , suggesting more robust replication in the primary nasal cells ( Figure 290 6Bvi ) . Collectively , these data indicate that virus infectivity / replication efficiency varies 291 markedly from proximal airway to alveolar respiratory regions . 292 Whole mount immunohistochemistry of HNE and LAE cultures was utilized to 293 identify cell types infected by SARS - CoV - 2 ( Figure 6C , S4A ) . The ciliated cell was 294 routinely infected and extruded . In contrast , the other major cell type facing the airway 295 lumen , i . e . , the MUC5B + club cell , was not infected , nor was the MUC5AC + metaplastic 296 goblet cell . We did note a cell type co - expressing the ciliated cell marker tubulin and 297 MUC5B was rarely infected in HNE , a finding consistent with infection of a 298 secretory / club cell transitioning to a ciliated cell phenotype . 299 There is debate whether AT2 and / or AT1 cells express sufficient ACE2 to 300 mediate infection and whether AT2 , AT1 , or both cell types are infectable . Previous 301 studies reported 2003 SARS - CoV infects AT2 but not AT1 pneumocytes ( Mossel et al . , 302 2008 ) . To focus on the relative infectivity by SARS - CoV - 2 for AT2 vs AT1 cells , 303 14 standard AT2 / AT1 cell cultures and a novel cell culture approach that well preserves 304 AT2 and AT1 cell populations over the infection / GFP expression interval were tested . 305 As shown in Figure 6A and S4B , AT2 cells appeared to be preferentially infected . 306 307 Respiratory tract region - specific aspects of SARS - CoV - 2 infectivity 308 We next investigated three other aspects of SARS - CoV - 2 infection of human 309 airway epithelia . First , the variability of infectivity among HNE and LAE cultures from 310 multiple donors was characterized . While all nine HNE and seven LAE were infected by 311 icSARS - CoV - 2 - GFP , marked variability in GFP signals per culture surface area and 312 viral growth curves were observed . LAE cultures exhibited higher variability in 313 susceptible cells than the HNE cultures at 72hpi ( Figures 6A , 6B , 6D and S4C ) . Ciliated 314 cell numbers in five LAE cultures were quantitated , and no correlation was noted 315 between susceptibility and ciliated cell percentages ( Figure 6Dii ) . 316 Second , to further characterize the infectivity of LAE vs SAE , replication rates of 317 three SARS - CoV - 2 viruses in LAE and SAE cultures from the same donor were 318 compared . All three viruses replicated more slowly in SAE than LAE cells . The GFP 319 virus replicated modestly less effectively than the clinical isolate or WT virus in the two 320 regions ( Figure 6E ) . This observation differs from the equivalent replication noted in the 321 Vero - E6 cells ( Figures 2A and 2B ) , suggesting an intact ORF7 gene contributes to 322 SARS - CoV - 2 replication , and perhaps virulence , in human tissues . 323 Third , the replication of SARS - CoV and SARS - CoV - 2 in LAE cells were 324 compared . SARS - Urbani WT and GFP viruses , in parallel with the three SARS - CoV - 2 325 viruses , were administered to LAE cultures from the same donor . GFP signals were 326 15 detected in LAE cultures for both viruses , but the SARS - CoV - 2 - GFP exhibited delayed 327 and less intense signals than SARS - CoV - Urbani - GFP ( Figure S4D ) . This phenotype is 328 consistent with the growth curve in which a lower titer of SARS - CoV - 2 was recorded at 329 24h . 330 331 SARS - CoV - 2 infection in COVID - 19 autopsy lungs 332 We utilized RNA - ISH / IHC to localize virus in four lungs from SARS - CoV - 2 - 333 infected deceased subjects ( Table S1 ) . Multiple observations at different length scales 334 were notable . First , at the macroscopic level , the infection appeared patchy , segmental , 335 and peripheral ( Figures 7A and S5A ) . These characteristics are consistent with an 336 aspiration distribution of an infectious inoculum . Second , ciliated cells within the 337 superficial epithelia lining proximal airway surfaces , particularly the trachea , were 338 infected ( Figure 7B and S5B ) . As observed in vitro , MUC5B + club and MUC5AC + 339 goblet cells were not infected in vivo . Third , the submucosal glands that populate the 340 large airway regions of the lung were not infected ( Figure S5C ) . Fourth , alveolar cells 341 were also infected . RNA in situ and IHC co - localization of an AT2 cell marker , SPC 342 ( SFTPC ) and AT1 cell marker ( AGER ) with SARS - CoV - 2 indicated that AT2 cells and 343 AT1 cells ( or AT2 cells that had transitioned to AT1 cells ) were infected ( Figure 7C and 344 S5D ) . 345 During the routine AB - PAS staining that detects mucins / mucin - like carbohydrates 346 in SARS - CoV - 2 - infected autopsy lungs , we noted faint AB - PAS staining in the 347 peripheral lung , i . e . , alveolar region in some lungs ( Figures 7D ) . Because aberrant 348 mucin secretion and accumulation is a feature of parenchymal diseases that can 349 16 progress to fibrosis , the AB - PAS material was characterized in more detail ( Figures 350 7Dii - 7Dv ) . IHC studies suggested that this material in large airways was a mixture of the 351 secreted mucins MUC5B and MUC5AC ( Figure 7Div ) . In the alveolar parenchymal 352 region , MUC5B alone was detected and was enriched in the peripheral subpleural area , 353 as often observed in idiopathic pulmonary fibrosis ( IPF ) ( Figure 7Dv ) ( Evans et al . , 354 2016 ) . Note , in none of the autopsy lungs studied was mechanical ventilation employed 355 and the lung in panels A and D of Figure 7 was immersion fixed . These observations , 356 coupled to the observation that MUC5AC was not detected in the peripheral region , 357 makes it unlikely that MUC5B selectively was mechanically spread from central to 358 peripheral lung zones . 359 360 Discussion 361 We generated a SARS - CoV - 2 reverse genetics system , characterized virus RNA 362 transcription profiles , evaluated the impact of ectopically expressed proteases on virus 363 growth , and used reporter viruses to characterize virus tropisms , ex vivo replication , and 364 to develop a high - throughput neutralizing assay . These reagents were utilized to 365 explore aspects of early infectivity and disease pathogenesis relevant to SARS - CoV - 2 366 respiratory infections . 367 Our RNAscope / cytospin technology extended the description of ACE2 in 368 respiratory epithelia based on scRNAseq data ( Sungnak et al . , 2020 ) . RNA / cytospin 369 detected ~ 20 % of upper respiratory cells expressing ACE2 vs ~ 4 % for scRNAseq 370 ( Figure 4F ) . Most of the RNA - ISH - detected ACE2 - expressing cells were ciliated cells , 371 not normal MUC5B + secretory ( club ) cells or goblet cells . Notably , the nose contained 372 17 the highest percentage of ACE2 - expressing ciliated cells in the proximal airways ( Figure 373 4G ) . The higher nasal ACE2 expression - level findings were confirmed by qPCR data 374 comparing nasal to bronchial airway epithelia . qPCR data also revealed that ACE2 375 levels further waned in the more distal bronchiolar and alveolar regions . Importantly , 376 these ACE2 expression patterns were paralleled by high SARS - CoV - 2 infectivity of 377 nasal epithelium with a gradient in infectivity characterized by a marked reduction in the 378 distal lung ( bronchioles , alveoli ) ( Figures 6A and 6B ) . 379 Multiple aspects of the variability in SARS - CoV - 2 infection of respiratory epithelia 380 were notable in these studies . First , significant donor variations in virus infectivity and 381 replication efficiency were observed . Notably , the variability was less in the nose than 382 lower airways . The reason ( s ) for the differences in lower airway susceptibility are 383 important but remain unclear ( Cockrell et al . , 2018 ) . We identified variations in ACE2 384 receptor expression ( Figures 4A - D ) but not numbers of ciliated cells as potential 385 variables ( Figure 6D ) . Second , variation in infectivity of a single cell type , i . e . , the 386 ciliated cell , was noted with only a fraction of ciliated cells having access to virus 387 infected at 72 h ( Figure 6A ) . Third , the dominant secretory cell , i . e . , the MUC5B + club 388 cell , was not infected in vitro or in vivo , despite detectable ACE2 and TMPRSS2 389 expression ( Figures 4G - 4I ) . Collectively , these data suggest that measurements of 390 ACE2 / TMPRSS2 expression do not fully describe cell infectivity and that a description 391 of other variables that mediate susceptibility to infection , including the innate immune 392 system ( s ) , is needed ( Menachery et al . , 2014 ) . 393 The ACE2 receptor gradient in the normal lung raised questions focused on the 394 initial sites of respiratory tract virus infection , the mechanisms that seed infection into 395 18 the deep lung , and the virus - host interaction networks that attenuate or augment intra - 396 regional virus growth in the lung to produce severe disease , especially in vulnerable 397 patients experiencing chronic lung or inflammatory diseases ( Guan et al . , 2020 ; Leung 398 et al . , 2020 ) . 399 We speculate that nasal surfaces may be the dominant initial site for SARS - CoV - 400 2 respiratory tract infection ( Wölfel et al . , 2020 ) . First , SARS - CoV - 2 RNA has been 401 detected in aerosol particles in the range of aerodynamic sizes exhaled during normal 402 tidal breathing ( Liu et al . , 2020 ; Papineni and Rosenthal , 1997 ) . Aerosol deposition and 403 fomite mechanical delivery deposition modeling suggest that aerosols containing virus 404 inhaled by naïve subjects achieve the highest density of deposition , i . e . , highest MOI 405 per unit surface area , in the nose ( Booth et al . , 2005 ; Farzal et al . , 2019 ; Teunis et al . , 406 2010 ) . Second , the relatively high ACE2 expression in nasal specimens and the parallel 407 high infectivity of the HNE cultures suggests the nasal cavity is a fertile site for early 408 SARS - CoV - 2 infection . Nasal infection likely is dominated by ciliated cells in the 409 superficial epithelium , not nasal submucosal glands . Third , the nose is exposed to high 410 but variable loads of environmental agents , producing a spectrum of innate defense 411 responses . Hence , a portion of the variability of the clinical syndrome of COVID - 19 may 412 be driven by environmentally driven variance nasal infectivity ( Wu et al . , 2020b ) . 413 Another aspect of the variability of the COVID - 19 syndrome is the variable 414 incidence and severity of lower lung disease . It is unlikely SARS - CoV - 2 is transmitted to 415 the lung by hematogenous spread , as demonstrated by the absence of infection of MVE 416 cells and previous reports that indicate airway cultures are difficult to infect from the 417 basolateral surface ( Sims et al . , 2005 ; Wölfel et al . , 2020 ) . Theoretically , infection could 418 19 be transmitted directly to lower lung surfaces by microaerosol inhalation with deposition 419 on and infection of alveolar surfaces mediated in part by the high ACE2 binding affinity 420 reported for SARS - CoV - 2 ( Shang et al . , 2020 ; Wrapp et al . , 2020 ) . However , given the 421 low levels of ACE2 expression in alveolar cells in health , the correlated poor infectivity 422 in vitro , and the absence of a homogeneous pattern radiographically , the importance of 423 this route remains unclear ( Santarpia et al . , 2020 ) . 424 In contrast , it is well - known that an oral – lung aspiration axis is a key contributor 425 to many lower airways infectious diseases ( Dickson et al . , 2016 ; Esther et al . , 2019 ; 426 Gaeckle et al . , 2020 ; Odani et al . , 2019 ; Phillips et al . , 2015 ) . Nasal secretions are 427 swept from the nasal surface rostrally by mucociliary clearance and accumulate in the 428 oral cavity at a rate of ~ 0 . 5 ml / hr where they are admixed with oropharyngeal / tonsillar 429 fluid ( Eichner et al . , 1983 ; Pandya and Tiwari , 2006 ) . Especially at night , it is predicted 430 that a bolus of relatively high titer virus is aspirated into the deep lung , either via 431 microaspiration or as part of gastro - esophageal reflex - associated aspiration , sufficient 432 to exceed the threshold PFU / unit surface area required to initiate infection ( Amberson , 433 1954 ; Gleeson et al . , 1997 ; Huxley et al . , 1978 ) . Note , our data that tracheas exhibited 434 significant viral infection in vivo suggest that small - volume microaspiration could also 435 seed this site . Tracheal - produced virus could then also accumulate in the oropharynx 436 via mucus clearance for subsequent aspiration into the deep lung ( Quirouette et al . , 437 2020 ) . Oropharyngeal aspirates also contain enzymes and / or inflammatory mediators 438 that may condition alveolar cells for infection . Aspiration of SARS - CoV - 2 into the lung is 439 consistent with the patchy , bibasilar infiltrates observed by chest CT in COVID - 19 ( Xu et 440 al . , 2020 ) . Notably , robust microaspiration and gastro - esophageal aspiration are 441 20 observed frequently in subjects who are at risk for more severe COVID - 19 lower 442 respiratory disease , e . g . , older , diabetic , and obese subjects ( Pan et al . , 2020a ; Phillips 443 et al . , 2015 ) . Finally , our autopsy studies demonstrated patchy , 444 segmental / subsegmental disease , consistent with aspiration of virus into the lung from 445 the oropharynx . 446 These speculations describing the early pathogenesis of SARS - CoV - 2 upper and 447 lower respiratory tract disease are consistent with recent clinical observations . The data 448 from Wölfel et al . ( 2020 ) in COVID - 19 - positive subjects support the concept of early 449 infection in the upper respiratory tract ( 0 - 5 d ) followed by subsequent aspiration and 450 infection of the lower lung . These authors focused on the oropharynx as a potential site 451 of the early virus propagation . As noted above , however , a nasal - oropharyngeal axis 452 also exists which has two implications . First , the nasal surfaces could seed the 453 oropharynx for infection . Second , it is likely that oropharyngeal secretions reflect a 454 mixture of local secretions admixed with a robust contribution of nasal mucus and virus . 455 Animal model data are also compatible with the scenario of aspiration - induced 456 focal SARS - CoV - 2 lung disease . The data of Rockx et al . ( 2020 ) noted focal lung 457 disease after combined intranasal / intratracheal dosing with SARS - CoV - 2 in cynomolgus 458 monkeys . Notably , other findings in this model phenocopied our observations of human 459 disease , e . g . , early nasal shedding of virus , infection of nasal ciliated cells , and infection 460 of AT2 and likely AT1 cells . Perhaps more definitive data describing nasal cavity 461 seeding of the lower lung by microaspiration emanate from the studies of Richard et al . 462 ( 2020 ) . These investigators demonstrated in ferret models that genetically marked virus 463 21 delivered to the nasal cavity more efficiently transmitted infection to the lower lungs than 464 a virus with a distinct genetic marker delivered directly into the lungs . 465 In addition to identifying possible microaspiration risk factors associated with 466 COVID - 19 disease severity in the elderly , diabetic , and obese , our studies provide 467 insights into variables that control disease severity in subjects at risk due to pre - existing 468 pulmonary disease ( Leung et al . , 2020 ; Sajuthi et al . , 2020 ) . For example , ACE2 469 expression was increased in the lungs of CF patients excised at transplantation . A 470 major cytokine that produces the muco - inflammatory CF airways environment , IL1 β , 471 was associated in vitro with increased ACE2 expression ( Chen et al . , 2019 ) . The clinical 472 outcome of increased ACE2 expression in CF is not yet known . The simple prediction is 473 that increased ACE2 expression might be associated with more frequent / severe SARS - 474 CoV - 2 disease in CF populations . However , increased ACE2 expression is reported to 475 be associated with improved lung function by negatively regulating ACE and the 476 angiotensin II and the angiotensin II type 1a receptor ( AT1a ) in models of alveolar 477 damage / pulmonary edema and bacterial infection ( Imai et al . , 2005 ; Jia , 2016 ; Keeler et 478 al . , 2018 ; Kuba et al . , 2005 ; Sodhi et al . , 2019 ) . Consequently , CF subjects might 479 exhibit reduced severity of disease once acquired . Data describing outcomes of COVID - 480 19 in the CF populations should emerge soon ( Colombo et al . , 2020 ) . 481 Our autopsy studies also provide early insights into the variable nature of the 482 severity and pathogenesis related to post - COVID - 19 lung health / function ( Atri et al . , 483 2020 ; Kollias et al . , 2020 ; Magro et al . , 2020 ) . Our study has identified another feature 484 of COVID - 19 , i . e . , the accumulation of apparently aberrantly secreted MUC5B in the 485 alveolar region . Accumulation of MUC5B in the peripheral / alveolar lung is characteristic 486 22 of subjects who develop idiopathic pulmonary fibrosis ( IPF ) , and polymorphisms in the 487 MUC5B promoter associated with IPF have been reported ( Evans et al . , 2016 ) . Future 488 studies of the long - term natural history of SARS - CoV - 2 survivors , in combination with 489 studies delineating the cell types responsible for MUC5B secretion ( AT2 vs airway cells ) 490 and genetics , e . g . , MUC5B polymorphisms , may aid in understanding the long - term 491 favorable vs fibrotic outcomes of COVID - 19 disease ( Chan et al . , 2003 ; Rogers et al . , 492 2018 ) . 493 Our study also provides a SARS - CoV - 2 infectious full - length cDNA clone for the 494 field . Several strategies have been developed to construct stable coronavirus molecular 495 clones , including the bacterial artificial chromosome ( BAC ) ( Almazan et al . , 2000 ; 496 Gonzalez et al . , 2002 ) and vaccinia viral vector systems ( Casais et al . , 2001 ) . In 497 contrast , our in vitro ligation method solves the stability issue by splitting unstable 498 regions and cloning the fragmented genome into separate vectors , obviating the 499 presence of a full - length genome ( Yount et al . , 2000 ) . Our in vitro ligation strategy has 500 generated reverse genetic systems for at least 13 human and animal coronaviruses and 501 produced hundreds of mutant recombinant viruses ( Beall et al . , 2016 ; Menachery et al . , 502 2015 ; Scobey et al . , 2013 ; Xie et al . , 2020 ; Yount et al . , 2003 ) . In contrast to other 503 reports ( Thao et al . , 2020 ) , reporter recombinant SARS - CoV - 2 viruses generated herein 504 replicated to normal WT levels in continuous cell lines , allowing for robust ex vivo 505 studies in primary cultures . 506 Using this infectious clone , we generated a high - throughput luciferase reporter 507 SARS - CoV - 2 assay for evaluation of viral nAbs . In line with previous reports ( Tian et al . , 508 2020 ; Wrapp et al . , 2020 ) , our data show that several SARS - CoV RBD - binding nAbs fail 509 23 to neutralize SARS - CoV - 2 , suggesting distant antigenicity within the RBD domains 510 between the two viruses . Although more samples are needed , early convalescent sera 511 demonstrated ~ 1 . 5 logs variation in neutralizing titers at ~ day 30 post - infection , 512 demonstrating a need to fully understand the kinetics , magnitude , and durability of the 513 neutralizing antibody response after a primary SARS - CoV - 2 infection . The detection of 514 low level SARS - CoV - 2 cross - neutralizing antibodies in 2003 SARS - CoV serum samples 515 is consistent with recent studies ( Hoffmann et al . , 2020 ; Walls et al . , 2020 ) , suggesting 516 that existence of common neutralizing epitopes between the two CoVs . Interestingly , 517 convalescent COVID - 19 sera failed to cross - neutralized SARS - CoV in vitro , suggesting 518 cross - neutralizing antibodies may be rare after SARS - CoV - 2 infection . The location of 519 these epitopes is unknown . The nLuc recombinant viruses described herein will be 520 powerful reagents for defining the antigenic relationships between the Sarbocoviruses , 521 the kinetics and durability of neutralizing antibodies after natural infection , and the 522 breadth of therapeutic neutralizing antibodies and vaccine countermeasures ( Wang et 523 al . , 2019 ) . 524 In summary , our studies have quantitated differences in ACE2 receptor 525 expression and SARS - CoV - 2 infectivity in the nose ( high ) vs the peripheral lung ( low ) . 526 These studies should provide valuable reference data for future animal models 527 development and expand the pool of tissues , e . g . , nasal , for future study of disease 528 pathogenesis and therapy . While speculative , if the nasal cavity is the initial site 529 mediating seeding of the lung via aspiration , these studies argue for the widespread use 530 of masks to prevent aerosol , large droplet , and / or mechanical exposure to the nasal 531 passages . Complementary therapeutic strategies that reduce viral titer in the nose early 532 24 in the disease , e . g . , nasal lavages , topical antivirals , or immune modulation , may be 533 beneficial . Finally , our studies provide key reagents and strategies to identify type 534 specific and highly conserved neutralizing antibodies that can be assessed most easily 535 in the nasal cavity as well as in the blood and lower airway secretions . 536 537 Acknowledgments 538 We would like to acknowledge the following funding sources from the National Allergy 539 and Infectious Disease ( NIAID ) , National Institution of Health ( NIH ) to R . S . B . ( U19 - 540 AI100625 , R01 - AI089728 , U01 - AI14964 ) , and National Heart , Lung , and Blood institute 541 ( NHLBI ) , NIH to R . C . B . ( UH3 - HL123645 , P01 - HL110873 , R01 - HL136961 , P30 - 542 DK065988 - 13 , P01 - HL108808 ) . K . O . is funded by the Cystic Fibrosis Foundation 543 ( OKUDA10I0 ) and a research grant from Cystic Fibrosis Research Incorporation . D . R . M . 544 is funded by an NIH NIAID T32 AI007151 and a Burroughs Wellcome Fund 545 Postdoctoral Enrichment Program Award . T . K . is funded by a Senior Research Training 546 Fellowship ( RT - 57362 ) of American Lung Association . A . J . K is support by National 547 Center for Advancing Translational Sciences , NIH , through grant # KL2TR002490 . We 548 thank N . J . Thornburg at CDC for providing us the SARS - CoV - 2 clinical isolate WA1 549 strain . We are grateful for the technical support of Y . Escobar for HNE cultures and Lisa 550 Morton for qPCR assays ; by S . Weiss , Y . Park , J . Kuruc and UNC Blood Donor Center 551 on COVID - 19 serum sample preparation . The UNC Animal Histopathology & Laboratory 552 Medicine Core is supported in part by an NCI Center Core Support Grant 553 ( 5P30CA016086 - 41 ) to the UNC Lineberger Comprehensive Cancer Center . We thank 554 25 E . C . Roe for assisting manuscript editing . Finally , we are grateful for the donors of 555 primary cells and sera who made this study possible . 556 557 558 Author Contributions 559 Conceptualization R . C . B . , R . S . B and S . H . R . ; Investigation : Y . J . H . , K . O . , C . E . E . , D . R . M . , 560 T . A . , K . D . 3 , T . K . , R . L . , B . L . Y . , T . M . M . , G . C . , K . N . O . , A . G . , L . V . T . , S . R . L . , L . E . G . , A . S . , 561 H . D . , R . G . , S . N . , L . S . , L . F . , W . K . O . , S . H . R . ; Contribution to research materials : A . L . B . , 562 N . I . N . , M . C . , C . C . , D . J . K . , A . D . S . , D . M . M . , A . M . , L . B . , R . Z . , F . J . M . , S . P . S . , A . B . , P . R . T . , 563 A . K . , I . J . , S . H . R . , Writing – original draft preparation : Y . J . H . ; Writing – review and 564 editing : R . C . B . , R . S . B . , S . H . R and W . K . O . ; Visualization : Y . J . H . , K . O . , C . E . E . , D . R . M . , 565 T . A . , T . K . ; Funding acquisition : R . C . B . and R . S . B . 566 567 Declaration of Interests 568 The authors declare no competing financial interests . 569 570 Figure legends 571 Figure 1 . See also Figure S1 . Design and recovery of SARS - CoV - 2 recombinant 572 viruses . ( A ) Full - length cDNA clone constructs and genomes of recombinant viruses . 573 Restriction sites , cohesive ends , and the genetic marker T15102A ( * ) are indicated in 574 the schematic diagram . GFP or GFP - fused nLuc genes were introduced into the ORF7 575 ( replacing aa # 14 - 104 ) of SARS - CoV - 2 genome . ( B ) Plaques of recombinant viruses . 576 ( C ) CPE and GFP signals were observed in Vero - E6 cells electroporated with sgRNA - N 577 26 alone ( mock ) or sgRNA - N mixed with full - length RNA transcripts ( recombinant viruses ) 578 at two days post - transfection . Scale bar = 100 µ m . SacI digestion ( D ) and Sanger 579 sequencing ( E ) of a 1 . 5kb region covering the genetic marker in vial genomes . ( F ) . 580 Northern blot analysis of genomic and sub - genomic ( sg ) RNAs isolated from the virus - 581 infected cells . Isolate : Clinical isolate strain WA1 ; WT : icSARS - CoV - 2 - WT ; GFP : 582 icSARS - CoV - 2 - GFP ; nLuc - GFP : icSARS - CoV - 2 - nLuc - GFP . 583 584 Figure 2 . See also Figure S2 . Growth curves and the role of proteases in SARS - 585 CoV - 2 replication . ( A ) One - step and ( B ) multi - step growth curves of clinical isolate and 586 recombinant viruses in Vero E6 cells , with MOI of 5 and 0 . 05 , respectively . Fluorescent 587 images ( C ) and viral titers ( D ) of the SARS - CoV - 2 - GFP replicates in Vero cells 588 supplemented with different concentrations of trypsin . Fluorescent images ( E ) and viral 589 titers ( F ) of the SARS - CoV - 2 - GFP replicates in normal Vero or Vero - furin cells . 590 Fluorescent images ( G ) and viral titers ( H ) of the SARS - CoV - 2 - GFP replicates in normal 591 LLC - MK or LLC - MK - TMPRSS2 cells . All scale bars = 200 µ m . Data are presented in 592 mean ± SD . 593 594 Figure 3 . Neutralization assays using luciferase reporter coronaviruses . ( A ) mAbs 595 and ( B ) COVID - 19 sera against icMERS - CoV - nLuc ; ( C ) mAbs and ( D ) SARS and 596 COVID - 19 sera against icSARS - CoV - nLuc ; ( E ) mAbs , ( F ) SARS and COVID - 19 sera , 597 and ( F ) vaccinated mouse serum against icSARS - CoV - 2 - nLuc - GFP ; ( H ) ID 50 values of 598 SARS and COVID - 19 sera cross - neutralizing SARS - CoV and SARS - CoV - 2 . The same 599 sera samples are indicated with arrows . MERS - CoV neutralizing mAbs : MERS - 27 , 600 27 m336 ; SARS - CoV neutralizing mAbs : S230 , S230 . 15 , S227 . 9 ; Dengue virus mAb : 601 EDE1 - C10 ; SARS patient serum samples : A to E ; COVID - 19 patient serum samples : 1 602 to 10 ; mouse serum was produced by immunized BALB / c mice with SARS - CoV - 2 spike . 603 604 Figure 4 . Intraregional ACE2 and TMPRSS2 mRNA expression in normal human 605 airways . See also Figure S3 . ( A ) Representative RNA in situ hybridization ( ISH ) 606 images demonstrating regional distribution of ACE2 and TMPRSS2 mRNA localization 607 ( red signal ) in normal human airway surface epithelium . Scale bars = 20 µ m . ( B ) 608 Comparison of ACE2 and TMPRSS2 mRNA expression between matched nasal and 609 bronchial brushed tissues obtained from 7 healthy subjects . ( C ) Relative expression of 610 ACE2 and TMPRSS2 mRNA in different airway regions enriched for epithelial cells , 611 including tracheas , bronchi , bronchiole , and alveoli , obtained from matched 7 normal 612 lungs . ( D ) Frequency of ACE2 and TMPRSS2 - positive cells among total cells identified 613 in distinct anatomical airway regions in a reanalysis of scRNA - seq data ( Deprez . M et 614 al . , BioRxiv , 2019 ) . ( E ) RNA - ISH images depicting mRNA expression of ACE2 and cell 615 type markers , including FOXJ1 ( ciliated ) ( Ei , ii , and iv ) , MUC5B ( secretory ) ( Eiii and v ) , 616 SFTPC ( alveolar type 2 ) ( Evi ) , and HOPX ( alveolar type 1 or 2 ) ( Evii ) on cytospins of 617 nasal / bronchial superficial epithelial and purified alveolar cells . Scale bars = 10 µ m . ( F ) 618 Frequency of ACE2 - positive cells among nasal and bronchial preparations . A total of 619 1 , 000 cells were analyzed for ACE2 expression per donor ( N = 3 ) . G . Frequency of 620 ACE2 - positive cells among FOXJ1 + or MUC5B + cells in nasal or bronchial preparations . 621 A total of 200 FOXJ1 + or MUC5B + cells were analyzed for ACE2 expression per donor 622 ( N = 3 ) . H , I . Histograms depicting number of dot signals of ACE2 expression in FOXJ1 623 28 or MUC5B + cells in nasal ( H ) or bronchial ( I ) preparations identified by scRNA - ISH . 624 ACE2 - positive dot signals were counted in 200 FOXJ1 or MUC5B - positive cells per 625 donor ( N = 3 ) . Statistics for B , C , F and G used linear mixed - effect model with donor as 626 random - effect factor for comparison between groups , and pair - wise comparisons of 627 groups with more than 2 levels were performed using Tukey post - hoc tests . H and I 628 used generalized linear mixed - effect models with Poisson distribution to compare the 629 difference in cell counts at varying ACE2 expression levels between FOXJ1 + and 630 MUC5B + cells . Histobars and error bars represent mean ± SD . Different symbol colors 631 indicate results from different individual donors . 632 633 Figure 5 . Inflammatory cytokines alter ACE2 and TMPRSS2 expression . ( A ) RNA in 634 situ hybridization images demonstrating regional distribution of ACE2 and TMPRSS2 635 mRNA localization in normal and CF human airways . Scale bars = 20 µ m . Images were 636 obtained from four different airway regions from one normal or CF subject as 637 representative of N = 6 normal or CF subjects studied . ( B ) mRNA expression of ACE2 638 and TMPRSS2 measured by Taqman assay after inflammatory cytokine challenge in 639 primary human large airway epithelial cells . Bi . IL1 β ( 10 ng / ml , 7 days , N = 8 ) . Bii . IFN β 640 ( 10 ng / ml , 3 days , N = 4 donors , 2 - 3 cultures / donor ) . Biii . IL13 ( 10 ng / ml , 7 days , N = 8 ) . 641 Wilcoxon matched - pairs signed rank test was used for comparison between control and 642 cytokine treatment groups . Histobars and error bars represent mean ± SD . Different 643 symbol colors indicate results from different individual donors . 644 645 29 Figure 6 . See also Figure S4 . Replication of SARS - CoV - 2 in primary human 646 respiratory cells . ( A ) Representative GFP signals in icSARS - CoV - 2 - GFP - infected HNE , 647 LAE , SAE , AT2 - like and AT - 1 like culture at 48h . Scale bar = 80 . ( B ) Growth curves of 648 icSARS - CoV - 2 - GFP in ( i ) HNE , n = 9 donors ; ( ii ) LAE , n = 7 donors ; ( iii ) SAE , n = 3 649 donors ; ( iv ) AT1 - like ( empty symbols ) and AT2 - like ( filled symbols ) cells , n = 3 650 donor / each . Cells from female and male donors are labeled in pink and blue , 651 respectively . Triplicated viral infection under MOI of 3 and 0 . 5 are shown in solid and 652 dotted lines , respectively . ( v ) Comparison of the highest titers of individual culture 653 among cell types ; ( vi ) Comparison of individual titers in HNE and LAE at different time 654 points . ( C ) Representative whole - mount extended focus views of icSARS - CoV - 2 - GFP - 655 infected HNE and LAE cell cultures . Red = filamentous actin ( phalloidin ) , White = α - 656 tubulin ( multiciliated cells ) , Green = GFP ( virus ) , Blue = nuclei ( Hoechst 33342 ) . Yellow 657 = MUC5B ( left ) . Yellow = MUC5AC ( right ) . Arrow : viral infected α - tubulin + ( ciliated ) / 658 MUC5B + ( secretory ) transitional HNEs . Scale bars = 50 µ m . ( D ) ( i ) Variability of GFP 659 and cilia signals in icSARS - CoV - 2 - GFP - infected LAE cultures collected from five 660 different donors at 72hpi , scale bar = 200 µ m . ( ii ) Quantification of ciliated area in the 661 LAE cultures . ( E ) Growth curves of icSARS - CoV - 2 - GFP infected in LAE and SAE 662 collected form the same donor . Cultures were infected with SARS - CoV - 2 clinical isolate 663 ( i ) , WT ( ii ) and GFP ( iii ) with MOI of 0 . 5 . Data are presented in mean ± SD . 664 665 Figure 7 . Characterization of cell types for SARS - CoV - 2 infection in SARS - CoV - 2 666 autopsy lungs . See also Figure S5 . ( A ) Sections from of an autopsy lung with SARS - 667 CoV - 2 infection were stained by hematoxylin and eosin ( i ) and probed for SARS - CoV - 2 668 30 by RNA in situ hybridization ( ISH ) ( ii - iv ) . SARS - CoV - 2 sense probe ( ii ) was used as a 669 negative control . Scale bars = 1 mm . ( B ) The trachea from a SARS - CoV - 2 autopsy was 670 probed for SARS - CoV - 2 by RNA ISH . ( i ) Colorimetric detection of SARS - CoV - 2 ( red ) 671 showing infection of surface epithelium . ( ii - iv ) Co - localization of SARS - CoV - 2 ( red ) with 672 cell - type - specific markers ( green ) determined by dual - immunofluorescent staining ( Bii , 673 acetylated α - tubulin cilia marker ; Biii , MUC5B secretory cell marker ; and Biv , MUC5AC 674 mucous / goblet - cell marker ) . Scale bars = 10 µ m . ( C ) Co - localization of SARS - CoV - 2 675 with alveolar cell - type - specific markers in the alveolar space from a SARS - CoV - 2 676 autopsy . ( i ) Dual color - fluorescent RNA ISH co - localization of SARS - CoV - 2 ( green ) with 677 alveolar type II cell marker SFTPC ( red ) . ( ii ) Dual - immunofluorescent co - localization of 678 SARS - CoV - 2 ( green ) with alveolar type I cell marker AGER ( magenta ) . Scale bars = 20 679 µ m . ( D ) Mucin expression in SARS - CoV - 2 autopsy lung . ( i ) Alcian Blue - periodic acid – 680 Schif ( AB - PAS ; blue to purple ) stain for complex carbohydrate ( mucin ) ; ( ii ) MUC5B 681 immunohistochemistry ; ( iii - v ) dual - immunofluorescent staining for MUC5B ( green ) and 682 MUC5AC ( red ) in the large airway ( iv ) and the alveoli ( v ) . SMG = submucosal grand . 683 Scale bars = 2mm ( i - iii ) ; 200 µ m ( iv and v ) . 684 685 STAR Methods 686 RESOURCE AVAILABILITY 687 Lead Contact 688 Further information and requests for resources and reagents should be directed to and 689 will be fulfilled by the Lead Contact , Ralph S . Baric ( rbaric @ email . unc . edu ) . 690 691 31 Materials Availability 692 Material and reagents generated in this study will be made available upon installment of 693 a material transfer agreement ( MTA ) . 694 695 Data and Code Availability 696 Genomic sequences of recombinant viruses icSARS - CoV - 2 - WT , icSARS - CoV - 2 - GFP 697 and icSARS - CoV - 2 - nLuc - GFP , which were generated in this study , have been 698 deposited to GenBank ( Accession # MT461669 to MT461671 ) . 699 700 EXPERIMENTAL MODEL AND SUBJECT DETAILS 701 Human Subjects 702 Excess surgical pathology tissues were obtained from the University of North Carolina 703 ( UNC ) Tissue Procurement and Cell Culture Core under protocol # 03 - 1396 approved by 704 the UNC Biomedical IRB . Informed consent was obtained from tissue donors or 705 authorized representatives . Cystic fibrosis lung tissue was obtained from donors 706 undergoing transplantation , while human lungs from previously healthy individuals 707 unsuitable for transplantation were obtained from Carolina Donor Services ( Durham , NC ) , 708 the National Disease Research Interchange ( Philadelphia , PA ) , or the International 709 Institute for Advancement of Medicine ( Edison , NJ ) . Upper airway tissues were obtained 710 from subjects undergoing elective surgeries . Excised tissue specimens were dissected 711 and fixed in 10 % neutral buffered formalin for 48 hours followed by paraffin - embedding . 712 The paraffin blocks were cut to produce 5 µ m serial sections for RNA - ISH and 713 immunohistochemistry . For qRT - PCR for ACE2 and TMPRSS2 expression in nasal and 714 32 bronchial epithelial cells , nasal and bronchial epithelial cells were obtained from 715 matched healthy volunteers by nasal scraping and bronchoscopic brush - biopsy under 716 the National Heart , Lung , and Blood Institute IRB - approved protocol # 07 - H - 0142 . For 717 single cell - RNA in situ hybridization ( scRNA - ISH ) , human bronchial epithelial cells were 718 obtained from the left main bronchus of healthy non - smoker volunteers by bronchoscopic 719 brush - biopsy under the UNC Biomedical IRB - approved protocol # 91 - 0679 . Nasal surface 720 epithelial cells were isolated from the resected nasal tissues as previously described 721 ( Fulcher and Randell , 2013 ; Okuda et al . , 2019 ) . After the isolation of nasal surface 722 epithelial cells , the remaining nasal tissues were micro - dissected to isolate submucosal 723 glands under the light microscope . Donor demographics was shown in Table S1 , S2 . 724 Tissue blocks or cut sections obtained from four COVID - 19 autopsy lungs were 725 obtained from Drs . Ross . E . Zumwalt ( University of New Mexico ) and Steven Salvatore 726 and Alain Borczuk ( New York Presbyterian Hospital ) . Donor demographics were 727 described as below . 728 Donor 1 . 40 - year - old , male . Medical history : Diabetes mellitus . Clinical course : 729 This donor had upper respiratory infection ( URI ) symptoms three days before he was 730 found dead at home . No intubation was conducted . Postmortem testing of the lung was 731 positive for SARS - CoV - 2 . 732 Donor 2 . 64 - year - old , male . Medical history : Diabetes mellitus , diabetic 733 nephropathy , hepatitis C , heart failure , and coronary artery disease . Clinical course : 734 This donor was transferred to ER because of fever and respiratory distress . Nasal swab 735 was positive for SARS - CoV - 2 . He died five hours after urgent care . No intubation was 736 conducted . 737 33 Donor 3 . 95 - year - old , female . Medical history : Hypertension , hyperlipidemia , 738 Alzheimer’s disease . Clinical course : This donor was transferred to ER because of 739 respiratory distress . Nasal swab was positive for SARS - CoV - 2 . She died 48 hours after 740 urgent care . No intubation was conducted . 741 Donor 4 . 69 - year - old , male . Medical history : acute myeloid leukemia , type 2 742 diabetes mellitus . Clinical course : This donor was admitted to the hospital because of 743 respiratory distress eight days after initial URI symptoms and diagnosis of SARS - CoV - 2 . 744 He died five days post admission . No intubation was conducted . 745 746 Primary Cell Culture 747 Primary human nasal epithelial cells ( HNE ) were collected from healthy volunteers by 748 curettage under UNC Biomedical IRB - approved protocols ( # 11 - 1363 and # 98 - 1015 ) 749 after informed consent as previously described ( Kesic et al . , 2011 ; Knowles et al . , 2014 ) . 750 Briefly , superficial scrape biopsies were harvested from the inferior nasal turbinates 751 under direct vision through a 9 mm reusable polypropylene nasal speculum ( Model 752 22009 ) on an operating otoscope with speculum ( Model 21700 ) . Both nostrils were 753 scraped 5 times without anesthesia using a sterile , plastic nasal curette ( Arlington 754 Scientific ) . Nasal cells were expanded using the conditionally reprogrammed cell ( CRC ) 755 method ( Gentzsch et al . , 2017 ) or in Pneumacult EX Plus media ( Stem Cell 756 Technologies ) ( Speen et al . , 2019 ) and then cultured on porous Transwell ( Corning ) 757 supports in Pneumacult air liquid interface ( ALI ) media ( Stem Cell Technologies ) . 758 Human bronchial epithelial [ large airway epithelial ( LAE ) ] and bronchiolar [ small airway 759 epithelial ( SAE ) ] cells , human alveolar type II pneumocytes ( AT2 ) , and human primary 760 34 lung microvascular endothelial cells ( MVE ) and fibroblasts ( FB ) were isolated from 761 freshly excised normal human lungs obtained from transplant donors with lungs 762 unsuitable for transplant under IRB - approved protocol ( # 03 - 1396 ) , as previously 763 described ( Fulcher and Randell , 2013 ; Okuda et al . , 2019 ) . 764 765 Cell Lines 766 Simian kidney cell lines Vero ( ATCC # CCL81 ) , Vero E6 ( ATCC # CRL1586 ) , and LLC - 767 MK ( ATCC # CCL - 7 ) were purchased from ATCC and preserved in our laboratory . The 768 Vero - furin cell line was reported previously ( Mukherjee et al . , 2016 ) . LLC - MK cells 769 expressing TMPRSS2 were generated in our laboratory . A novel immortalized nasal cell 770 line ( UNCNN2TS ) was created by lentiviral over expression of Bmi - 1 and hTERT 771 ( Fulcher et al . , 2009 ) in primary nasal cells , and subsequent lentiviral addition of SV40 T 772 antigen ( pBSSVD2005 was a gift from David Ron , Addgene plasmid # 21826 ) . 773 UNCNN2T cells are grown and infected in EpiX media ( Propagenix ) . 774 775 Virus strains 776 Clinical SARS - CoV - 2 isolate WA1 strain was provided by Dr . Natalie J . Thornburg at the 777 U . S . Centers for Disease Control and Preventive ( CDC ) . The virus was isolated from 778 the first US COVID - 19 patient identified in Washington state ( GenBank Accession # : 779 MT020880 ) . Recombinant CoVs icSARS - CoV - Urbani , icSARS - CoV - GFP , icSARS - CoV - 780 nLuc and icMERS - CoV - nLuc were generated in our laboratory as described previously 781 ( Scobey et al . , 2013 ; Yount et al . , 2003 ) . Briefly , the strategy to synthesize full - length 782 cDNA clones for SARS - CoV - Urbani and MERS - CoV was identical to the method 783 35 reported herein , but with different restriction sites and junctions . The GFP and nLuc 784 reporters were inserted into the accessory ORF7a of the icSARS - CoV - Urbani clone , 785 whereas the nLuc reporter gene was introduced into the accessory ORF5a of the 786 icMERS - CoV clone . Virus stocks were propagated on Vero E6 cells in minimal essential 787 medium containing 10 % fetal bovine serum ( HyClone ) and supplemented with 788 penicillin / kanamycin ( Gibico ) . Virus plaques were visualized by neutral red staining at 789 two days post - infection . The UNC Institutional Biosecurity Committee and the National 790 Institute of Allergy and Infectious Disease ( NIAID ) have approved the SARS - CoV - 2 791 molecular clone project . All viral infections were performed under biosafety level 3 ( BSL - 792 3 ) conditions at negative pressure , and Tyvek suits connected with personal powered - 793 air purifying respirators . 794 795 Human serum samples 796 SARS serum samples were obtained from SARS convalescent patients from University 797 Health Network , MaRS Center , Toronto , Canada that had a confirmed SARS infection 798 under IRB - approved protocol ( # UHN REB 03 - 0250 ) . COVID - 19 serum samples were 799 also provided as coded material and were deemed " not human subject research " by the 800 UNC School of Medicine Biomedical IRB ( # 20 - 1141 ) . 801 802 METHOD DETAILS 803 Primary human cell culture and infection 804 Nasal cells were expanded using the conditionally reprogrammed cell ( CRC ) method 805 ( Gentzsch et al . , 2017 ) or in Pneumacult EX Plus media ( Stem Cell Technologies ) 806 36 ( Speen et al . , 2019 ) and then cultured on porous Transwell ( Corning ) supports in 807 Pneumacult air liquid interface ( ALI ) media ( Stem Cell Technologies ) . Human LAE and 808 SAE cells were cultured as previously described ( Fulcher and Randell , 2013 ; Okuda et 809 al . , 2019 ) . Briefly , Isolated LAE and SAE cells were co - cultured with mitomycin - treated 810 3T3 J2 cells on collagen - coated tissue culture plastic dishes in DMEM media 811 supplemented with 10 µ M Y - 27632 ( Enzo Life Science ) . At 70 - 90 % confluence , LAE 812 and SAE cells were passaged and sub - cultured for expansion . P2 LAE and SAE cells 813 were transferred to human placental type IV collagen - coated , 0 . 4 µ m pore size Millicell 814 inserts ( Millipore , PICM01250 ) . The LAE and SAE cells were seeded at a density of 2 . 8 815 × 10 5 cells / cm 2 and cultured in UNC ALI media . Upon confluence , cells were maintained 816 at an ALI by removing apical media and providing UNC ALI media to the basal 817 compartment only . Medium was replaced in the basal compartment twice a week , and 818 the apical surfaces were washed with PBS once a week . After 28 days , LAE and SAE 819 cells were utilized for SARS - CoV - 2 recombinant viruses infection . Human type II 820 pneumocytes ( AT2 ) were prepared and cultured on porous supports as previously 821 described ( Bove et al . , 2010 ) . The AT2 cells are grown in DMEM with P / S and 10 % FBS 822 and switched to 4 % FBS 24 hours prior to infection . Cells were studied within three days 823 and after five days , as they transdifferentiate into type I pneumocyte ( AT1 ) - like cells . For 824 serum - free and feeder - free AT2 cell cultures ( mixed AT1 / AT2 culture ) , human lung 825 pieces ( ~ 2gm ) were washed twice with PBS containing 1 % Antibiotic - Antimycotic and 826 cut into small pieces . Visible small airways and blood vessels were carefully removed to 827 avoid clogging . Then samples were digested with 30 ml of enzyme mixture ( collagenase 828 type I : 1 . 68 mg / ml , dispase : 5U / ml , DNase : 10U / ml ) at 37°C for 45 min with rotation . 829 37 The cells were filtered through a 100 µm strainer and rinsed with 15 ml PBS through the 830 strainer . The supernatant was removed after centrifugation at 450x g for 10 min and the 831 cell pellet was resuspended in red blood cell lysis buffer for five minutes , washed with 832 DMEM / F12 containing 10 % FBS and filtered through a 40 µm strainer . To purify human 833 AT2 cells , approximately two million total lung cells were resuspended in SF medium 834 and incubated with Human TruStain FcX ( BioLegend ) followed by incubation with HTII - 835 280 antibody ( Terrace Biotech ) . The cells were washed with PBS and then incubated 836 with anti - mouse IgM microbeads . The cells were loaded into LS column ( Miltenyi Biotec ) 837 and labeled cells collected magnetically . HTII - 280 + human AT2 cells ( 1 - 3 × 10 3 ) were 838 resuspended in culture medium . Serum - free feeder free medium and AT2 differentiation 839 medium will be described elsewhere ( S . V . and PRT et al . , currently under revision in 840 Cell Stem Cell ) . Culture plates were coated with Cultrex reduced growth factor 841 basement membrane extract , Type R1 and cultured for five days followed by changing 842 medium to AT2 differentiation medium for additional five days . 843 Human primary lung microvascular endothelial cells ( MVE ) and fibroblasts ( FB ) 844 were grown as previously described ( Scobey et al . , 2013 ) . For MVE cells , peripheral 845 lung tissue minus the pleura was minced , digested with dispase / elastase , and cells 846 were grown in EGM - 2 media plus FBS ( Lonza ) . Two or three rounds of CD31 bead 847 purification ( Dynabeads ; Life Technologies ) resulted in > 95 % CD31 - positive cells by 848 flow cytometry that were used between passages 5 and 10 . FBs were obtained by finely 849 mincing distal human lung tissue and plating on scratched type 1 / 3 collagen - coated 850 dishes in Dulbecco ' s modified Eagle medium with high glucose ( DMEMH ) media plus 10 % 851 FBS , antibiotics , and antimycotics . Cells were released using trypsin / EDTA and 852 38 subcultured in DMEMH , 10 % FBS and P / S . The subcultured cells were elongated , 853 spindly and negative for CD31 and pan - cytokeratin by flow cytometry and 854 immunofluorescence , respectively . 855 icSARS - CoV - 2 - GFP virus infections were performed using well differentiated air - 856 liquid interface ( ALI ) cultures of five donor specimens of human nasal epithelial ( HNE ) 857 and large airway epithelial ( LAE ) cells using an MOI of three . Small airway epithelial 858 ( SAE ) cell ALI cultures were created as previously described ( Okuda et al . , 2019 ) . 859 Paired LAE / SAE cells were inoculated with a SARS - CoV - 2 clinical isolate , icSARS - 860 CoV - 2 - WT , and icSARS - CoV - 2 - GFP , as well as wild - type icSARS - CoV - Urbani and 861 icSARS - CoV - GFP on LAE , using an MOI of 0 . 5 for each virus . Transwell - cultured 862 primary cells were inoculated with 200ul of virus v ia the apical surface and allowed to 863 incubate at 37 (cid:176) C for two hours . Following incubation , virus was removed , and cells were 864 washed twice with 500ul PBS . Cells were returned to 37 (cid:176) C for the remainder of the 865 experiment and observed for fluorescent signal , when appropriate , every 12 - 24 hours . 866 100ul PBS was added to the apical surface of each culture and allowed to incubate for 867 10 minutes at 37 (cid:176) C in order to obtain an apical wash sample , at time points for analysis 868 of viral replication by plaque assay . At the last time point , cells were lysed with 500ul 869 TRIzol reagent ( Invitrogen ) to obtain total final RNA for analysis . 870 871 Primary human bronchial epithelial cell culture and cytokines exposure : Primary 872 human LAE cells from normal donors ( obtained from donors without previously known 873 pulmonary diseases ) were cultured on the human placenta collagen IV ( Sigma Cat # C - 874 7521 ) coated transwell ( Corning Cat # 3640 ) under air - liquid interface ( ALI ) condition . 875 39 The apical surface was washed with PBS , and ALI medium ( Fulcher et al . , 2009 ) was 876 replaced only in the basal compartment two - three times per week , and cells were 877 cultured under ALI conditions for four weeks to allow full differentiation . Exposure with 878 recombinant human cytokines was administrated started at the 5 th week after ALI 879 culture . All recombinant human cytokines ( IL1 β at 10ng / ml , IL13 at 10ng / ml , and IFN β 880 at 10ng / m of final concentration in ALI media ) were added to basolateral side of ALI 881 media , and media were changed after three days supplied with freshly diluted cytokines . 882 Cells were collected at day five – day seven for RNA isolation . 883 884 Whole - mount immunostaining and imaging . 885 Well - differentiated mock or icSARS - CoV - 2 - GFP - infected LAE ALI cultures were fixed 886 twice for 10 minutes in 4 % formaldehyde in PBS and washed and stored in PBS . The 887 GFP signal was enhanced by staining with anti - GFP antibody ( Abcam ab6556 ; 0 . 5 888 ug / mL ) , a Venezuelan equine encephalitis virus ( VEEV ) - like replicon particle - immunized 889 mouse antiserum against SARS - CoV - 2 N protein ( 1 : 4000 dilution ) and polyclonal rabbit 890 anti - SARS - CoV N protein ( Invitrogen PA1 - 41098 , 0 . 5 ug / mL ) using species - specific 891 secondary antibodies as previously described ( Ghosh et al . , 2018 ) . The cultures were 892 also imaged for a - tubulin ( Millipore MAB1864 ; 3ug / mL ) , MUC5AC ( ThermoScientific 893 45M1 ; 4ug / mL ) , MUC5B [ polyclonal rabbit against a MUC5B peptide ( MAN5BII ) , 1 : 1000 ] 894 ( Thornton et al . , 2000 ) , and CCSP ( Sigma 07 - 623 ; 1 : 2000 ) as indicated . Filamentous 895 actin was localized with phalloidin ( Invitrogen A22287 ) , and DNA with Hoechst 33342 896 ( Invitrogen ) . An Olympus FV3000RS confocal microscope in Galvo scan mode was 897 used to acquire 5 - channel Z stacks by 2 - phase sequential scan . Representative stacks 898 40 were acquired with a 60X oil objective ( xyz = 212um x 212um x ~ 25um ) , and are shown 899 as Z - projections or single - slice , XZ cross sections to distinguish individual cell features 900 and to characterize the infected cell types . A 20X objective was used to acquire 2D , 901 single - channel , apical snapshots of nine fields ( 636um x 636um ; combined area = 902 3 . 64mm 2 ) , selected in evenly spaced grids across each sham infected donor culture , 903 and ImageJ was used to measure the relative apical culture surface covered by 904 multiciliated cells . 905 906 Immunohistochemistry 907 Immunohistochemical staining was performed on COVID - 19 autopsy lung sections 908 according to a protocol as previously described ( Okuda et al . , 2019 ) . Briefly , paraffin - 909 embedded sections were baked at 60 °C for 2 – 4 hours , and deparaffinized with xylene 910 ( 2 changes × 5 min ) and graded ethanol ( 100 % 2 × 5 min , 95 % 1 × 5 min , 70 % 1 × 5 911 min ) . After rehydration , antigen retrieval was performed by boiling the slides in 0 . 1 M 912 sodium citrate pH 6 . 0 ( 3 cycles with microwave settings : 100 % power for 6 . 5 min , 913 60 % for 6 min , and 60 % for 6 min , refilling the Coplin jars with distilled water after each 914 cycle ) . After cooling and rinsing with distilled water , quenching of endogenous 915 peroxidase was performed with 0 . 5 % hydrogen peroxide in methanol for 15 min , slides 916 washed in PBS , and blocked with 4 % normal donkey serum , for an hour at RT . Primary 917 antibody ( MUC5AC : 45M1 , 1 : 1000 , MUC5B : H300 , 1 : 1000 , SARS - CoV - 2 nucleocapsid : 918 1 : 500 , Anti - SARS mouse antiserum : 1 : 4000 , Acetylated - α - tubulin : 1 : 1000 , AGER : 1 : 400 ) 919 were diluted in 4 % normal donkey serum in PBST and incubated over night at 4 °C . 920 Mouse and rabbit gamma globulin was used as an isotype control at the same 921 41 concentration as the primary antibody . Sections were washed in PBST and secondary 922 antibodies ( biotinylated donkey anti - rabbit IgG , at 1 : 200 dilution in 4 % normal donkey 923 serum in PBST for chromogenic DAB staining for MUC5B , Alexa Fluor 488 donkey anti - 924 rabbit IgG , at 1 : 1000 dilution and Alexa Fluor 594 donkey anti - mouse IgG , at 925 1 : 1000 dilution for fluorescent staining ) were applied for 60 min at RT . After washing in 926 PBST , the Vector® TrueVIEW Autofluorescence Quenching Kit ( Vector laboratories ) 927 was used to reduce background staining , and glass coverslips were placed over tissue 928 sections with the ProLong Gold Antifade Reagent with DAPI ( Invitrogen ) for fluorescent 929 staining . For chromogenic DAB staining , slides were incubated with avidin - peroxidase 930 complex according to the manufacturer’s instructions ( Vectastain kit , Vector 931 laboratories ) , washed , incubated with the chromogenic substrate ( Immpact Novared , 932 Vector laboratories ) and counterstained with Fast Red . Coverslipped slides were 933 scanned and digitized using an Olympus VS120 whole slide scanner microscope with a 934 40X / 60X 0 . 95 NA objective and Olympus confocal microscope with a 40X 0 . 6 NA or 935 60X 1 . 4 NA objective . 936 937 Cell dissociation for single cell - RNA in situ hybridization ( scRNA - ISH ) 938 Fresh bronchoscopically brush - biopsied human main bronchial epithelial cells , nasal 939 surface epithelial and submucosal gland cells isolated from the resected nasal tissues 940 were incubated with Accutase solution for 30 min at 37°C . The Accutase - treated cells 941 were centrifuged ( 450 g , 2 min , 4°C ) and then incubated with 10 mL HBSS ( Ca + , Mg + ) 942 buffer containing DNase I ( 0 . 1 mg / ml ) ( Roche # 10104159001 ) and collagenase IV ( 1 943 mg / ml ) ( Gibco # 17104 - 019 ) for 10 min and 30 min for bronchial / nasal surface epithelial 944 42 cell and nasal submucosal gland cell isolation , respectively at 37°C with intermittent 945 agitation . Nasal submucosal glands were micro - dissected from the nasal tissues under 946 microscopy . The tissues were centrifuged ( 450 g , 2 min , 4°C ) and then incubated with 10 947 mL HBSS ( Ca + , Mg + ) buffer containing DNase I ( 0 . 1 mg / ml ) and collagenase IV ( 1 mg / ml ) 948 for 30 min at 37°C with intermittent agitation followed by additional incubation with 949 Trypsin - EDTA ( Final concentration : 0 . 125 % , Gibco # 25200 - 056 ) for 20 min at 37°C . After 950 incubation , enzymes were inactivated by adding 500 µ L fetal bovine serum . Dissociated 951 cells were filtered through a 40 - µ m cell strainer , centrifuged ( 450 g , 2 min , 4°C ) and 952 resuspended in PBS , adjusted to 10 5 cells / ml . Cell viability was examined by trypan 953 blue dye exclusion . Single cell suspension was cytocentrifuged ( 55 g , 4 min , StatSpin 954 CytoFuge2 , Beckman Coulter ) and fixed in 10 % NBF for 30 min at room temperature . 955 The cytocentrifuged cells were washed with PBS three times and then dehydrated with 956 graded ethanol ( 50 % 1 min , 70 % 1 min , 100 % 1 min ) . The slides were stored in 100 % 957 ethanol at - 20°C until future use for scRNA - ISH . 958 959 RNA in situ hybridization 960 RNA - ISH was performed on cytocentrifuged single cells using the RNAscope Multiplex 961 Fluorescent Assay v2 , and on paraffin - embedded 5 µ m tissue sections using the 962 RNAscope 2 . 5 HD Reagent Kit and RNAscope 2 . 5 HD Duplex Reagent Kit according to 963 the manufacturer’s instructions ( Advanced Cell Diagnostics ) . Cytospin slides were 964 rehydrated with graded ethanol ( 100 % 1 min , 70 % 1 min , 50 % 1 min ) , permeabilized 965 with PBS + 0 . 1 % Tween 20 ( PBST ) at RT for 10 min , incubated with hydrogen peroxide 966 ( Advanced Cell Diagnostics ) at RT for 10 min , followed by incubation with 1 : 15 diluted 967 43 protease III at RT for 10 min . Tissue sections were deparaffinized with xylene ( 2 968 changes × 5 min ) and 100 % ethanol ( 2 changes × 1 min ) , and then incubated with 969 hydrogen peroxide for 10 min , followed by target retrieval in boiling water for 15 min , 970 and incubation with Protease Plus ( Advanced Cell Diagnostics ) for 15 min at 40 °C . 971 Slides were hybridized with custom probes at 40 °C for 2 hours , and signals were 972 amplified according to the manufacturer’s instructions . The stained sections were 973 scanned and digitized using an Olympus VS120 light or fluorescent microscope with a 974 40X 1 . 35 NA objective and Olympus confocal microscope with a 40X 0 . 6 NA or 60X 1 . 4 975 NA objective . 976 977 Calculation of frequency of ACE2 and TMPRSS2 - positive cells in distinct 978 anatomical airway regions as identified by scRNA - seq 979 Normalized log - transformed count + 1 gene x cell matrix and meta - data were 980 downloaded from https : / / www . genomique . eu / cellbrowser / HCA / , which represent 77 , 969 981 cells that passed quality control . Expression of ACE2 and TMPRSS2 were extracted 982 from the matrix , and the number of cells with log normalized count > 0 were calculated . 983 984 RNA isolation and gene expression analysis by Taqman Assays 985 For qRT - PCR for ACE2 and TMPRSS2 expression in different airway regions , surface 986 epithelial cells were isolated from freshly excised normal human lungs obtained from 987 transplant donors by gentle scraping with a convex scalpel blade into F12 medium , 988 excluding submucosal glands . Following centrifugation ( 450 g , 5 min , 4 °C ) , the pelleted 989 epithelial cells were resuspended in 1 ml of TRI Reagent ( Sigma ) . Micro - dissected small 990 44 airways and peripheral lung parenchyma were homogenized in 1 ml of TRI Reagent 991 using a tissue homogenizer ( Bertin Technologies ) . Debris was pelleted from the TRI 992 Reagent by centrifugation , and the supernatant was used for RNA analysis . 993 The HBE cells growing on the transwell membrane were collected by excision of 994 the whole membrane together with the cells using razor blade and lysed in TRI Reagent 995 at 37°C shaker for 30 minutes . Total RNA was purified from the TRI Reagent lysates 996 using the Direct - Zol RNA miniprep Kit ( Zymo Research , cat # R2051 ) , and examined by 997 NanoDrop One Spectrophotometer ( ThermoFisher ) for its quality and quantity . 1 µ g of 998 total RNA was reverse transcribed to cDNA by iScript™ Reverse Transcription 999 Supermix ( BioRad , Cat # 1708840 ) at 42°C for one hour . Quantitative RT - PCR was 1000 performed using Taqman probes ( Applied BioSystems ) with SsoAdvanced Universal 1001 Probes Supermix ( Bio - Rad , cat # 1725280 ) on QuantStudio6 Real - time PCR machine 1002 ( Applied Biosystem ) . The house - keeping gene used for normalization of gene 1003 expression for in vitro cultured HBE was TATA - binding protein ( TBP ) gene . See Key 1004 Resource Table for detailed information about primers / probes . 1005 1006 Assembly of SARS - CoV - 2 WT and reporter cDNA constructs 1007 Seven cDNA fragments covering the entire SARS - CoV - 2 WA1 genome were amplified 1008 by RT - PCR using PrimeSTAR GXL HiFi DNA polymerase ( TaKaRa ) . Junctions between 1009 each fragment contain non - palindromic sites BsaI ( GGTCTCN ^ NNNN ) or BsmBI 1010 ( CGTCTCN ^ NNNN ) with unique four - nucleotide cohesive ends . Fragment E and F 1011 contains two BsmBI sites at both termini , while other fragments harbor BsaI sites at the 1012 junction . Four - nucleotide cohesive ends of each fragment are indicated in Figure 1A . To 1013 45 assist the transcription of full - length viral RNA , we introduced a T7 promoter sequence 1014 into the upstream of fragment A , as well as a 25nt poly - A tail into the downstream of the 1015 fragment G . Each fragment was cloned into high - copy vector pUC57 and verified by 1016 Sanger sequencing . A silent mutation T15102A was introduced into a conserved region 1017 in nsp12 in plasmid D as a genetic marker . To enhance the efficiency of recovering 1018 SARS - CoV - 2 virus in the cell culture , a sgRNA - N construct , encoding a 75nt leader 1019 sequence , N gene , 3 ' UTR , and a 25nt poly - A tail , was assembled under the control of a 1020 T7 promoter . Two reporter viruses , one containing GFP and the other harboring , a GFP - 1021 fused nLuc gene , were generated by replacing the ORF7 gene with the reporter genes . 1022 1023 Generation of full - length RNA transcript and recovery of recombinant viruses 1024 Seven genomic cDNA fragments were digested with appropriate endonucleases , 1025 resolved on 0 . 8 % agarose gels , excised and purified using a QIAquick Gel Extraction kit 1026 ( Qiagen ) . A full - length genomic cDNA was obtained by ligating seven fragments in an 1027 equal molar ratio with T4 DNA ligase ( NEB ) . We then purified the ligated cDNA with 1028 chloroform and precipitated it in isopropanol . The full - length viral RNA or SARS - CoV - 2 1029 sgRNA - N were synthesized using the T7 mMESSAGE mMACHINE T7 transcription kit 1030 ( Thermo Fisher ) at 30 ℃ for 4h . The full - length SARS - CoV - 2 transcript and sgRNA - N 1031 were mixed and electroporated into 8×10 6 of Vero E6 cells . The cells were cultured as 1032 usual in the medium for two to three days . 1033 1034 PCR of leader - containing sgRNAs 1035 46 Viral replication in the electroporated cells was evaluated by amplification of leader 1036 sequence - containing sgRNAs . A forward primer targeting the leader sequence ( 5 ' - 1037 GTTTATACCTTCCCAGGTAACAAACC - 3’ ) was paired with a reverse primer targeting 1038 M gene ( 5 ' - AAGAAGCAATGAAGTAGCTGAGCC - 3’ ) or N gene ( 5 ' - 1039 GTAGAAATACCATCTTGGACTGAGATC - 3’ ) . 1040 1041 Identification of the genetic marker 1042 To confirm that the introduced T15102A mutation exists in the recombinant viruses , viral 1043 RNA was extracted using TRI Reagent ( Thermo Fisher ) . A 1579 bp fragment in nsp12 1044 of each virus was amplified by RT - PCR using primer pair 5’ - 1045 GCTTCTGGTAATCTATTACTAGATAAACG - 3’ and 5’ - 1046 AAGACATCAGCATACTCCTGATTAGG - 3’ . The fragment was subjected to Sanger 1047 sequencing or digested with SacI enzyme ( NEB ) . 1048 1049 Northern Blot Analysis 1050 Vero E6 cells were infected with SARS - CoV - 2 isolate , icSARS - CoV - 2 - WT , icSARS - 1051 CoV - 2 - GFP or icSARS - CoV - 2 - GFP - nLuc at an MOI of 1 . At 24hr post - infection , we 1052 extracted the total cellular RNA using TRIzol Reagent ( Thermo Fisher ) . Poly A - 1053 containing messenger RNA was isolated from the total RNA using an Oligotex mRNA 1054 Mini Kit ( Qiagen ) . Messenger RNA ( 0 . 6 - 0 . 7 µ g ) was separated on an agarose gel and 1055 transferred to BrightStar - Plus membrane using a NorthernMax - Gly Kit ( Invitrogen ) . Blots 1056 were hybridized with a biotin - labeled oligomer ( 5 ' - 1057 BiodT / GGCTCTGTTGGGAATGTTTTGTATGCG / BiodT - 3’ ) , then detected using a 1058 47 Chemiluminescent Nucleic Acid Detection Module ( Thermo Fisher ) using the iBright 1059 Western Blot Imaging System ( Thermo Fisher ) . 1060 1061 Generation of SAR - CoV - 2 S protein - immunized mouse serum 1062 The SAR - CoV - 2 S and N genes was cloned into pVR21 3526 to generate virus replicon 1063 particles ( VRPs ) , as previously described ( Agnihothram et al . , 2018 ) . Briefly , SARS - 1064 CoV - 2 S or N genes were inserted into pVR21 , a vector encoding the genome of a 1065 VEEV strain 3526 . The SARS - CoV - 2 - S - pVR21 construct , a plasmid containing the 1066 VEEV envelope glycoproteins , and a plasmid encoding the VEEV capsid protein were 1067 used to generate T7 RNA transcripts . The RNA transcripts were then electroporated 1068 into BHK cells . VRPs were harvested 48 hours later and purified via high - speed ultra - 1069 centrifugation . Two groups of 10 - week - old BALB / c mice ( Jackson Labs ) were then 1070 inoculated with the VRPs via footpad injection then boosted with the same dose once 1071 four weeks later . Serum samples were collected at 2 weeks post - boosting and were 1072 mixed together . 1073 1074 Monoclonal antibody large - scale production 1075 SARS - specific S230 , S230 . 15 , S227 . 14 , S227 . 9 IgG , MERS - specific MERS - 27 , m336 1076 IgG , and a Dengue - specific EDE1 - C10 IgG antibody variable heavy and light chain 1077 genes were obtained , codon - optimized for human mammalian cell expression , and 1078 cloned into heavy and light - chain variable - gene - expressing plasmids encoding a human 1079 IgG1 Fc region as described previously ( Martinez et al . , 2020 ) . One hundred m g of each 1080 variable heavy and light chain plasmids were co - transfected using an ExpiFectamine 1081 48 293 transfection kit in Expi293F ( Thermo ) cells at 2 . 5 million cells / ml in 1L flasks in 1082 suspension . Transfected cell supernatants were harvested two days later , and the 1083 soluble antibody was purified using Pierce protein A beads ( Thermo ) followed by fast 1084 protein liquid chromatography ( FPLC ) . MAbs were buffer exchanged with sterile 1XPBS . 1085 Purified mAbs were quality controlled by Western blotting and Coomassie blue staining 1086 to confirm mAb purity . 1087 1088 MERS - CoV , SARS - CoV , and SARS - CoV - 2 neutralization assays 1089 Recombinant viruses icMERS - CoV - nLuc , icSARS - CoV - nLuc , and icSARS - CoV - 2 - nLuc - 1090 GFP were tittered in Vero E6 cells to obtain a relative light units ( RLU ) signal of at least 1091 20X the cell only control background . Vero E6 cells were plated at 20 , 000 cells per well 1092 the day prior in clear bottom black - walled 96 - well plates ( Corning 3904 ) . Neutralizing 1093 antibody serum samples were tested at a starting dilution of 1 : 20 and mAb samples 1094 were tested at a starting dilution 50 m g / ml and were serially diluted 4 - fold up to eight 1095 dilution spots . icMERS - CoV - nLuc , icSARS - CoV - nLuc , and icSARS - CoV - 2 - nLuc - GFP 1096 viruses were diluted and were mixed with serially diluted antibodies . Antibody - virus 1097 complexes were incubated at 37 (cid:176) C with 5 % CO2 for 1 hour . Following incubation , 1098 growth media was removed , and virus - antibody dilution complexes were added to the 1099 cells in duplicate . Virus - only controls and cell - only controls were included in each 1100 neutralization assay plate . Following infection , plates were incubated at 37 (cid:176) C with 5 % 1101 CO2 for 48 hours . After the 48 hours incubation , cells were lysed , and luciferase activity 1102 was measured via Nano - Glo Luciferase Assay System ( Promega ) according to the 1103 manufacturer specifications . MERS - CoV , SARS - CoV , and SARS - CoV - 2 neutralization 1104 49 titers were defined as the sample dilution at which a 50 % reduction in RLU was 1105 observed relative to the average of the virus control wells . 1106 1107 QUANTIFICATION AND STATISTICAL ANALYSIS 1108 For comparison of gene expression in response to cytokine exposure versus 1109 control ( PBS ) with one culture per code in each group , we performed Wilcoxon 1110 matched - pairs signed rank test by Graphpad Prism 8 built in function . For comparison of 1111 gene expression in response to cytokine exposure vs control ( PBS ) with more than one 1112 culture per code in each group , the linear mixed - effect models analysis were performed . 1113 The relative mRNA expression from Taqman assays were analyzed with linear mixed - 1114 effect models using the R package Ime4 ( Bates et al . , 2015 ) , with treatment as fixed 1115 effect and code as random - effect factors . Statistical significance were evaluated with 1116 the R lmerTest package ( Kuznetsova et al . , 2017 ) , using the Satterthwarte’s degrees of 1117 freedom method . Multiple post - hoc comparisons of subgroups were performed using 1118 the R multcomp package ( Hothorn T , 2008 ) . For cell count data , generalized linear 1119 mixed - effect models ( glmer ) with Poisson distribution was used . Wilcoxon rank sum test 1120 was used to determine the statistical significance between unpaired two groups in 1121 Figure 2 ( D , F and H ) , and Figure 6 Bvi using Graphpad Prism 8 . One - way ANOVA 1122 followed by Tukey test was used to determine the statistical significance between 1123 groups in Figure 6Bv using Graphpad Prism 8 . The “n” numbers for each experiment 1124 are provided in the text and figures . P < 0 . 05 was considered statistically significant . 1125 1126 Co - localization of ACE2 mRNA with marker - genes and quantification 1127 50 RNA - ISH was performed on cytocentrifuged single cells using RNAscope Multiplex 1128 Fluorescent Assay v2 , as described above , to assess colocalization of ACE2 mRNA 1129 and airway epithelial cell markers , including FOXJ1 ( ciliated cells ) and MUC5B 1130 ( secretory cells ) . ACE2 probe ( channel 1 ) was combined with each of airway epithelial 1131 cell marker ( channel 2 ) . The stained cytospin slides were scanned and digitized using 1132 an Olympus VS120 whole slide scanner microscope with a 40X 0 . 9 numerical aperture 1133 objective . Using Fiji software ( Schindelin et al . , 2012 ) , quantification for colocalization 1134 was performed in the scanned images by an investigator blinded to slide identification . 1135 To calculate the occurrence of ACE2 + cells in preparations , ACE2 + cells and total cells 1136 were manually counted , and the frequency calculated . For quantitative co - localization 1137 analysis of ACE2 with airway epithelial marker - defined cells , the number of visible 1138 ACE2 signals ( dots ) was manually counted in each airway epithelial cell - marker - positive 1139 cell . The ACE2 + signals were quantitated in 200 FOXJ1 + or MUC5B + cells per subject . 1140 One or more dot signals defined a n ACE2 + positive cell , while airway - epithelial - marker - 1141 positive cells were defined as cells expressing 10 or more dot signals for the epithelial 1142 marker . 1143 1144 Quantification of ACE2 and TMPRSS2 gene expression in tonsillar surface 1145 epithelium 1146 Human tonsil tissue sections were analyzed for ACE2 and TMPRSS2 expression using 1147 RNA - ISH . Tonsillar surface epithelial regions with positive RNA ISH signals ( 4 to 8 1148 regions per donor ) were selected for quantification . Signal counts were normalized to 1149 the number of cells as determined by DAPI nuclear stain in each region . For 1150 51 quantification , the stratified epithelial layer was divided into two layers : 1 ) surface 1151 ( flattened epithelial ) layer and 2 ) basal ( cuboidal epithelial ) layer . 1152 1153 52 Supplemental Information 1154 1155 Figure S1 . Additional information for the SARS - CoV - 2 infectious cDNA clone , 1156 Related to Figure 1 . ( A ) Electrophoresis of seven restriction enzyme - digested 1157 infectious cDNA clone plasmids . Plasmid A was digested with NotI and BsaI ; plasmids 1158 B , C , and D were digested with BsaI ; plasmids E and F were digested with BsmBI ; 1159 plasmid G was digested with SalI and BsaI . ( B ) Amplification SARS - CoV - 2 sgRNAs 1160 using primers targeting sgRNA - 5 ( M ) and - 9 ( N ) . Cellular RNA samples were collected 1161 from Vero - E6 cells electroporated with viral RNA transcripts at 20h . Mock cells were 1162 electroporated with SARS - CoV - 2 sgRNA - 9 alone . ( C ) Alignment of sequences 1163 containing the T # 15102 in nsp12 gene among 9 different group 2b CoVs . 1164 1165 Figure S2 . Cytopathic effect of cells infected with icSARS - CoV - GFP virus , Related 1166 to Figure 2 . ( A ) Infected Vero cells supplemented with different concentrations of 1167 trypsin . ( B ) Infected Vero or Vero - furin cells . ( C ) Infected LLC - MK or LLC - MK - 1168 TMPRSS2 cells . All scale bars = 200 µ m . 1169 1170 Figure S3 . ACE2 and TMPRSS2 expression in human tonsillar epithelium and 1171 nasal surface epithelium and submucosal glands , Related to Figure 4 ( A ) Tonsillar 1172 surface squamous epithelium stained with ( Ai ) H & E staining and ( Aii ) dual - color - 1173 fluorescence RNA - ISH showing TMPRSS2 ( green ) and ACE2 ( red ) along with nuclear 1174 staining ( blue ) . Scale bars = 50 um . ( iii ) Enlarged images of Aii showing surface ( iii ) and 1175 basal ( iv ) expression ; scale bars = 20um . Images are representative from N = 3 tonsils , 1176 53 N = 4 - 8 regions per tonsil . ( Av ) Signal dots for ACE2 and TMPRSS2 mRNAs were 1177 counted and normalized to the number of cells in surface and basal layer of tonsillar 1178 surface epithelium as described in the STAR methods . Each bar represents the average 1179 of N = 4 - 8 regions for each tonsil studied . ( B ) Frequency of FOXJ1 - or MUC5B - positive 1180 cells identified by RNA - ISH among total nasal surface epithelial cells isolated . A total of 1181 1 , 000 cells were analyzed for FOXJ1 or MUC5B expression per donor . N = 3 . ( C ) 1182 Cytospins of nasal submucosal glands cells probed by dual - color - immunofluorescent 1183 RNA - ISH . Ci shows lack of ACE2 in MUC5B - positve nasal gland cells , while Cii depicts 1184 occasional co - expression of TMPRSS2 in a subset of MUC5B - positive cells . Scale bars 1185 = 20 µ m . ( Ciii ) Frequency of detection of ACE2 or TMPRSS2 positive cells in MUC5B 1186 positive cells from nasal glands . N = 1 gland preparation , a total of 200 MUC5B positive 1187 cells were counted . 1188 1189 Figure S4 . Additional data of SARS - CoV and SARS - CoV - 2 infected primary human 1190 cells , Related to Fig . 6 . ( A ) Representative whole - mount extended focus views of 1191 icSARS - CoV - 2 - GFP - infected ( i ) HNE and LAE cell cultures . Red = filamentous actin 1192 ( phalloidin ) , White = α - tubulin ( multiciliated cells ) , Blue = nuclei ( Hoechst 33342 ) . Green 1193 = GFP ( left ) . Green = SARS - CoV - 2 Nucleocapsid ( right ) . Yellow = MUC5AC ( left ) . 1194 Yellow = MUC5B ( right ) ; ( ii ) LAE and SAE cell cultures . Yellow = filamentous actin 1195 ( phalloidin ) , White = α - tubulin ( multiciliated cells ) , Blue = nuclei ( Hoechst 33342 ) . Green 1196 = GFP ( virus ) . Red = CCSP . Scale bars = 50 µ m . ( B ) Merged of GFP and bright field 1197 mages taken from AT1 and AT2 cells infected with icSARS - CoV - 2 - GFP at 48h . The AT - 1198 1 cells are present inside the enclosed areas . Bar = 100 µ m . ( C ) GFP signals of 1199 54 icSARS2 - GFP - infected HNEs collected from five different donors at 72hpi , MOI = 3 . ( D ) 1200 ( i ) Fluorescent signals of the two viruses in LAE ( ii ) Growth curves of three SARS - CoV - 1201 2 viruses in LAE from the same donor . Scale bar = 200 µ m . ( iii ) Growth curves of two 1202 SARS - Urbani viruses in LAE . All the infections in this figure were in MOI = 0 . 5 . 1203 1204 Figure S5 . SARS - CoV - 2 infection in SARS - CoV - 2 autopsy lungs , Related to Figure 1205 7 . ( A ) Sections from of a second region of an autopsy lung with SARS - CoV - 2 infection 1206 were stained by hematoxylin and eosin ( H & E ) ( i ) and probed for SARS - CoV - 2 by RNA 1207 in situ hybridization ( ISH ) ( ii , iii , and iv ) . Related to Figure 7A . ( B ) Frequency of 1208 acetylated alpha tubulin , MUC5AC , or MUC5B colocalization with SARS - CoV - 2 positive 1209 cells in the trachea from a SARS - CoV - 2 autopsy . A total of 200 randomly selected 1210 SARS - CoV - 2 positive cells were analyzed for each dual staining condition . Related to 1211 Figure 7B ii , iii , iv . ( C ) Absence of SARS - CoV - 2 infection in submucosal glands ( SMG ) . 1212 ( Ci - ii ) H & E staining ( i ) and RNA - ISH ( ii ) for SARS - CoV - 2 ( red ) in a large cartilaginous 1213 airway of one autopsy lung . SARS - CoV - 2 is only present in the surface epithelium near 1214 the lumen , not in SMG . ( Ciii - iv ) H & E ( iii ) and dual - immunofluorescence staining using 1215 acetylated alpha tubulin ( red ) and anti - SARS - CoV - 2 rabbit polyclonal antibody ( green ) 1216 ( iv ) from the trachea of a separate autopsy . Related to Figure 7B and S5Di . ( D ) 1217 Regional distribution of SARS - CoV - 2 RNA from trachea to alveoli identified by RNA - ISH 1218 in one SARS - 2 - CoV autopsy lung ( in i and ii , viral staining is red ; in iii , viral staining is 1219 turquoise ) . RNA - ISH dual color images demonstrate SARS - CoV - 2 RNA and SFTPC 1220 mRNA ( alveolar type 2 cell marker ) localization in alveoli of a SARS - CoV - 2 autopsy 1221 55 lung . SARS - CoV - 2 ( turquoise ) was identified in a SFTPC ( red ) - positive ( iii , arrow ) and a 1222 SFTPC - negative cell ( iv , arrowhead ) ; Scale bars = 2mm ( A ) ; 100 µ m ( C ) ; 20 µ m ( D ) . 1223 References 1224 Agnihothram , S . , Menachery , V . D . , Yount , B . L . , Jr . , Lindesmith , L . C . , Scobey , T . , 1225 Whitmore , A . , Schafer , A . , Heise , M . T . , and Baric , R . S . ( 2018 ) . Development of a 1226 broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine 1227 platform . J . Virol . 92 . 1228 Aguiar , J . A . , Tremblay , B . J . - M . , Mansfield , M . J . , Woody , O . , Lobb , B . , Banerjee , A . , 1229 Chandiramohan , A . , Tiessen , N . , Dvorkin - Gheva , A . , Revill , S . , et al . ( 2020 ) . Gene 1230 expression and in situ protein profiling of candidate SARS - CoV - 2 receptors in human 1231 airway epithelial cells and lung tissue . bioRxiv , 1232 http : / / dx . doi . org / 10 . 1101 / 2020 . 04 . 07 . 030742 . 1233 Almazan , F . , Gonzalez , J . M . , Penzes , Z . , Izeta , A . , Calvo , E . , Plana - Duran , J . , and 1234 Enjuanes , L . ( 2000 ) . Engineering the largest RNA virus genome as an infectious 1235 bacterial artificial chromosome . Proc . Natl . Acad . Sci . U . S . A . 97 , 5516 - 5521 . 1236 Amberson , J . B . ( 1954 ) . A clinical consideration of abscesses and cavities of the lung . 1237 Bull . Johns Hopkins Hosp . 94 , 227 - 237 . 1238 Andersen , K . G . , Rambaut , A . , Lipkin , W . I . , Holmes , E . C . , and Garry , R . F . ( 2020 ) . The 1239 proximal origin of SARS - CoV - 2 . Nat . Med . 26 , 450 - 452 . 1240 Atri , D . , Siddiqi , H . K . , Lang , J . , Nauffal , V . , Morrow , D . A . , and Bohula , E . A . ( 2020 ) . 1241 COVID - 19 for the cardiologist : a current review of the virology , clinical epidemiology , 1242 cardiac and other clinical manifestations and potential therapeutic strategies . JACC 1243 Basic Transl . Sci . , http : / / dx . doi . org / 10 . 1016 / j . jacbts . 2020 . 04 . 002 . 1244 Bates , D . , Mächler , M . , Bolker , B . , and Walker , S . ( 2015 ) . Fitting linear mixed - effects 1245 models using lme4 . J . Stat . Softw . 67 , 1 - 48 . 1246 Beall , A . , Yount , B . , Lin , C . M . , Hou , Y . , Wang , Q . , Saif , L . , and Baric , R . ( 2016 ) . 1247 Characterization of a pathogenic full - length cDNA clone and transmission model for 1248 porcine epidemic diarrhea virus strain PC22A . mBio 7 , e01451 - 01415 . 1249 Booth , T . F . , Kournikakis , B . , Bastien , N . , Ho , J . , Kobasa , D . , Stadnyk , L . , Li , Y . , Spence , 1250 M . , Paton , S . , Henry , B . , et al . ( 2005 ) . Detection of airborne severe acute respiratory 1251 syndrome ( SARS ) coronavirus and environmental contamination in SARS outbreak 1252 units . J . Infect . Dis . 191 , 1472 - 1477 . 1253 Boucher , R . C . ( 2019 ) . Muco - obstructive lung diseases . N . Engl . J . Med . 380 , 1941 - 1953 . 1254 56 Bove , P . F . , Grubb , B . R . , Okada , S . F . , Ribeiro , C . M . , Rogers , T . D . , Randell , S . H . , 1255 O ' Neal , W . K . , and Boucher , R . C . ( 2010 ) . Human alveolar type II cells secrete and 1256 absorb liquid in response to local nucleotide signaling . J . Biol . Chem . 285 , 34939 - 34949 . 1257 Brann , D . , Tsukahara , T . , Weinreb , C . , Logan , D . W . , and Datta , S . R . ( 2020 ) . Non - neural 1258 expression of SARS - CoV - 2 entry genes in the olfactory epithelium suggests 1259 mechanisms underlying anosmia in COVID - 19 patients . bioRxiv , 1260 http : / / dx . doi . org / 10 . 1101 / 2020 . 03 . 25 . 009084 . 1261 Carsana , L . , Sonzogni , A . , Nasr , A . , Rossi , R . , Pellegrinelli , A . , Zerbi , P . , Rech , R . , 1262 Colombo , R . , Antinori , S . , Corbellino , M . , et al . ( 2020 ) . Pulmonary post - mortem findings 1263 in a large series of COVID - 19 cases from Northern Italy . medRxiv , 1264 http : / / dx . doi . org / 10 . 1101 / 2020 . 04 . 19 . 20054262 . 1265 Casais , R . , Thiel , V . , Siddell , S . G . , Cavanagh , D . , and Britton , P . ( 2001 ) . Reverse 1266 genetics system for the avian coronavirus infectious bronchitis virus . J . Virol . 75 , 12359 - 1267 12369 . 1268 CDC COVID - 19 Response Team ( 2020 ) . Preliminary estimates of the prevalence of 1269 selected underlying health conditions among patients with coronavirus disease 2019 - 1270 United States , February 12 - March 28 , 2020 . MMWR Morb . Mortal . Wkly . Rep . 69 , 382 - 1271 386 . 1272 Chan , K . S . , Zheng , J . P . , Mok , Y . W . , Li , Y . M . , Liu , Y . N . , Chu , C . M . , and Ip , M . S . ( 2003 ) . 1273 SARS : prognosis , outcome and sequelae . Respirology 8 Suppl , S36 - 40 . 1274 Chen , G . , Sun , L . , Kato , T . , Okuda , K . , Martino , M . B . , Abzhanova , A . , Lin , J . M . , Gilmore , 1275 R . C . , Batson , B . D . , O ' Neal , Y . K . , et al . ( 2019 ) . IL - 1beta dominates the promucin 1276 secretory cytokine profile in cystic fibrosis . J . Clin . Invest . 129 , 4433 - 4450 . 1277 Cockrell , A . S . , Johnson , J . C . , Moore , I . N . , Liu , D . X . , Bock , K . W . , Douglas , M . G . , 1278 Graham , R . L . , Solomon , J . , Torzewski , L . , Bartos , C . , et al . ( 2018 ) . A spike - modified 1279 Middle East respiratory syndrome coronavirus ( MERS - CoV ) infectious clone elicits mild 1280 respiratory disease in infected rhesus macaques . Sci . Rep . 8 , 10727 . 1281 Colombo , C . , Burgel , P . R . , Gartner , S . , van Koningsbruggen - Rietschel , S . , Naehrlich , L . , 1282 Sermet - Gaudelus , I . , and Southern , K . W . ( 2020 ) . Impact of COVID - 19 on people with 1283 cystic fibrosis . Lancet Respir . Med . 8 , e35 - e36 . 1284 Coutard , B . , Valle , C . , de Lamballerie , X . , Canard , B . , Seidah , N . G . , and Decroly , E . 1285 ( 2020 ) . The spike glycoprotein of the new coronavirus 2019 - nCoV contains a furin - like 1286 cleavage site absent in CoV of the same clade . Antiviral Res . 176 , 104742 . 1287 Deprez , M . , Zaragosi , L . - E . , Truchi , M . , Garcia , S . R . , Arguel , M . - J . , Lebrigand , K . , 1288 Paquet , A . , Pee’r , D . , Marquette , C . - H . , Leroy , S . , et al . ( 2019 ) . A single - cell atlas of the 1289 human healthy airways . bioRxiv , http : / / dx . doi . org / 10 . 1101 / 2019 . 12 . 21 . 884759 . 1290 57 Dickson , R . P . , Erb - Downward , J . R . , Martinez , F . J . , and Huffnagle , G . B . ( 2016 ) . The 1291 microbiome and the respiratory tract . Annu . Rev . Physiol . 78 , 481 - 504 . 1292 Durante , M . A . , Kurtenbach , S . , Sargi , Z . B . , Harbour , J . W . , Choi , R . , Kurtenbach , S . , 1293 Goss , G . M . , Matsunami , H . , and Goldstein , B . J . ( 2020 ) . Single - cell analysis of olfactory 1294 neurogenesis and differentiation in adult humans . Nat . Neurosci . 23 , 323 - 326 . 1295 Eichner , H . , Behbehani , A . A . , and Hochstrasser , K . ( 1983 ) . [ Diagnostic value of nasal 1296 secretions , current state : normal values . 1 ] . Laryngol . Rhinol . Otol . ( Stuttg ) 62 , 561 - 565 . 1297 Esther , C . R . , Jr . , Muhlebach , M . S . , Ehre , C . , Hill , D . B . , Wolfgang , M . C . , Kesimer , M . , 1298 Ramsey , K . A . , Markovetz , M . R . , Garbarine , I . C . , Forest , M . G . , et al . ( 2019 ) . Mucus 1299 accumulation in the lungs precedes structural changes and infection in children with 1300 cystic fibrosis . Sci . Transl . Med . 11 . 1301 Evans , C . M . , Fingerlin , T . E . , Schwarz , M . I . , Lynch , D . , Kurche , J . , Warg , L . , Yang , I . V . , 1302 and Schwartz , D . A . ( 2016 ) . Idiopathic pulmonary fibrosis : a genetic disease that 1303 involves mucociliary dysfunction of the peripheral airways . Physiol . Rev . 96 , 1567 - 1591 . 1304 Farzal , Z . , Basu , S . , Burke , A . , Fasanmade , O . O . , Lopez , E . M . , Bennett , W . D . , Ebert , 1305 C . S . , Jr . , Zanation , A . M . , Senior , B . A . , and Kimbell , J . S . ( 2019 ) . Comparative study of 1306 simulated nebulized and spray particle deposition in chronic rhinosinusitis patients . Int . 1307 Forum Allergy Rhinol . 9 , 746 - 758 . 1308 Fulcher , M . L . , Gabriel , S . E . , Olsen , J . C . , Tatreau , J . R . , Gentzsch , M . , Livanos , E . , 1309 Saavedra , M . T . , Salmon , P . , and Randell , S . H . ( 2009 ) . Novel human bronchial epithelial 1310 cell lines for cystic fibrosis research . Am . J . Physiol . Lung Cell . Mol . Physiol . 296 , L82 - 1311 91 . 1312 Fulcher , M . L . , and Randell , S . H . ( 2013 ) . Human nasal and tracheo - bronchial respiratory 1313 epithelial cell culture . Methods Mol . Biol . 945 , 109 - 121 . 1314 Gaeckle , N . T . , Pragman , A . A . , Pendleton , K . M . , Baldomero , A . K . , and Criner , G . J . 1315 ( 2020 ) . The oral - lung axis : the impact of oral health on lung health . Respir . Care , 1316 http : / / dx . doi . org / 10 . 4187 / respcare . 07332 . 1317 Gentzsch , M . , Boyles , S . E . , Cheluvaraju , C . , Chaudhry , I . G . , Quinney , N . L . , Cho , C . , 1318 Dang , H . , Liu , X . , Schlegel , R . , and Randell , S . H . ( 2017 ) . Pharmacological rescue of 1319 conditionally reprogrammed cystic fibrosis bronchial epithelial cells . Am . J . Respir . Cell 1320 Mol . Biol . 56 , 568 - 574 . 1321 Ghosh , A . , Coakley , R . C . , Mascenik , T . , Rowell , T . R . , Davis , E . S . , Rogers , K . , Webster , 1322 M . J . , Dang , H . , Herring , L . E . , Sassano , M . F . , et al . ( 2018 ) . Chronic e - cigarette exposure 1323 alters the human bronchial epithelial proteome . Am J . Respir . Crit . Care Med . 198 , 67 - 1324 76 . 1325 Gleeson , K . , Eggli , D . F . , and Maxwell , S . L . ( 1997 ) . Quantitative aspiration during sleep 1326 in normal subjects . Chest 111 , 1266 - 1272 . 1327 58 Gonzalez , J . M . , Penzes , Z . , Almazan , F . , Calvo , E . , and Enjuanes , L . ( 2002 ) . 1328 Stabilization of a full - length infectious cDNA clone of transmissible gastroenteritis 1329 coronavirus by insertion of an intron . J . Virol . 76 , 4655 - 4661 . 1330 Gorbalenya , A . E . , Baker , S . C . , Baric , R . S . , de Groot , R . J . , Drosten , C . , Gulyaeva , A . A . , 1331 Haagmans , B . L . , Lauber , C . , Leontovich , A . M . , Neuman , B . W . , et al . ( 2020 ) . The 1332 species Severe acute respiratory syndrome - related coronavirus : classifying 2019 - nCoV 1333 and naming it SARS - CoV - 2 . Nat . Microbiol . 5 , 536 - 544 . 1334 Guan , W . J . , Liang , W . H . , Zhao , Y . , Liang , H . R . , Chen , Z . S . , Li , Y . M . , Liu , X . Q . , Chen , 1335 R . C . , Tang , C . L . , Wang , T . , et al . ( 2020 ) . Comorbidity and its impact on 1590 patients 1336 with Covid - 19 in China : a nationwide analysis . Eur . Respir . J . , 1337 http : / / dx . doi . org / 10 . 1183 / 13993003 . 00547 - 2020 . 1338 Hoffmann , M . , Kleine - Weber , H . , Schroeder , S . , Kruger , N . , Herrler , T . , Erichsen , S . , 1339 Schiergens , T . S . , Herrler , G . , Wu , N . H . , Nitsche , A . , et al . ( 2020 ) . SARS - CoV - 2 cell 1340 entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease 1341 inhibitor . Cell 181 , 271 - 280 . e278 . 1342 Huang , C . , Wang , Y . , Li , X . , Ren , L . , Zhao , J . , Hu , Y . , Zhang , L . , Fan , G . , Xu , J . , Gu , X . , 1343 et al . ( 2020 ) . Clinical features of patients infected with 2019 novel coronavirus in Wuhan , 1344 China . Lancet 395 , 497 - 506 . 1345 Huxley , E . J . , Viroslav , J . , Gray , W . R . , and Pierce , A . K . ( 1978 ) . Pharyngeal aspiration in 1346 normal adults and patients with depressed consciousness . Am . J . Med . 64 , 564 - 568 . 1347 Imai , Y . , Kuba , K . , Rao , S . , Huan , Y . , Guo , F . , Guan , B . , Yang , P . , Sarao , R . , Wada , T . , 1348 Leong - Poi , H . , et al . ( 2005 ) . Angiotensin - converting enzyme 2 protects from severe 1349 acute lung failure . Nature 436 , 112 - 116 . 1350 Izaguirre , G . ( 2019 ) . The proteolytic regulation of virus cell entry by furin and other 1351 proprotein convertases . Viruses 11 . 1352 Jia , H . ( 2016 ) . Pulmonary angiotensin - converting enzyme 2 ( ACE2 ) and inflammatory 1353 lung disease . Shock 46 , 239 - 248 . 1354 Keeler , S . P . , Agapov , E . V . , Hinojosa , M . E . , Letvin , A . N . , Wu , K . , and Holtzman , M . J . 1355 ( 2018 ) . Influenza A virus infection causes chronic lung disease linked to sites of active 1356 viral RNA remnants . J . Immunol . 201 , 2354 - 2368 . 1357 Kesic , M . J . , Simmons , S . O . , Bauer , R . , and Jaspers , I . ( 2011 ) . Nrf2 expression modifies 1358 influenza A entry and replication in nasal epithelial cells . Free Radic . Biol . Med . 51 , 444 - 1359 453 . 1360 Knowles , M . R . , Ostrowski , L . E . , Leigh , M . W . , Sears , P . R . , Davis , S . D . , Wolf , W . E . , 1361 Hazucha , M . J . , Carson , J . L . , Olivier , K . N . , Sagel , S . D . , et al . ( 2014 ) . Mutations in 1362 RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype . Am 1363 J . Respir . Crit . Care Med . 189 , 707 - 717 . 1364 59 Kollias , A . , Kyriakoulis , K . G . , Dimakakos , E . , Poulakou , G . , Stergiou , G . S . , and Syrigos , 1365 K . ( 2020 ) . Thromboembolic risk and anticoagulant therapy in COVID - 19 patients : 1366 emerging evidence and call for action . Br . J . Haematol . , 1367 http : / / dx . doi . org / 10 . 1111 / bjh . 16727 . 1368 Kuba , K . , Imai , Y . , Rao , S . , Gao , H . , Guo , F . , Guan , B . , Huan , Y . , Yang , P . , Zhang , Y . , 1369 Deng , W . , et al . ( 2005 ) . A crucial role of angiotensin converting enzyme 2 ( ACE2 ) in 1370 SARS coronavirus - induced lung injury . Nat . Med . 11 , 875 - 879 . 1371 Kuznetsova , A . , Brockhoff , P . B . , and Christensen , R . H . B . ( 2017 ) . lmerTest package : 1372 tests in linear mixed effects models . J . Stat . Softw . 82 , 1 - 26 . 1373 Leung , J . M . , Yang , C . X . , Tam , A . , Shaipanich , T . , Hackett , T . L . , Singhera , G . K . , 1374 Dorscheid , D . R . , and Sin , D . D . ( 2020 ) . ACE - 2 expression in the small airway epithelia of 1375 smokers and COPD patients : implications for COVID - 19 . Eur . Respir . J . , 1376 http : / / dx . doi . org / 10 . 1183 / 13993003 . 00688 - 2020 . 1377 Liu , Y . , Ning , Z . , Chen , Y . , Guo , M . , Liu , Y . , Gali , N . K . , Sun , L . , Duan , Y . , Cai , J . , 1378 Westerdahl , D . , et al . ( 2020 ) . Aerodynamic analysis of SARS - CoV - 2 in two Wuhan 1379 hospitals . Nature , http : / / dx . doi . org / 10 . 1038 / s41586 - 020 - 2271 - 3 . 1380 Magro , C . , Mulvey , J . J . , Berlin , D . , Nuovo , G . , Salvatore , S . , Harp , J . , Baxter - Stoltzfus , 1381 A . , and Laurence , J . ( 2020 ) . Complement associated microvascular injury and 1382 thrombosis in the pathogenesis of severe COVID - 19 infection : a report of five cases . 1383 Transl . Res . , http : / / dx . doi . org / 10 . 1016 / j . trsl . 2020 . 04 . 007 . 1384 Martinez , D . R . , Tu , J . J . , Kumar , A . , Mangold , J . F . , Mangan , R . J . , Goswami , R . , Giorgi , 1385 E . E . , Chen , J . , Mengual , M . , Douglas , A . O . , et al . ( 2020 ) . Maternal broadly neutralizing 1386 antibodies can select for neutralization - resistant , infant - transmitted / founder HIV variants . 1387 mBio 11 . 1388 Matsuyama , S . , Nagata , N . , Shirato , K . , Kawase , M . , Takeda , M . , and Taguchi , F . 1389 ( 2010 ) . Efficient activation of the severe acute respiratory syndrome coronavirus spike 1390 protein by the transmembrane protease TMPRSS2 . J . Virol . 84 , 12658 - 12664 . 1391 Matsuyama , S . , Ujike , M . , Morikawa , S . , Tashiro , M . , and Taguchi , F . ( 2005 ) . Protease - 1392 mediated enhancement of severe acute respiratory syndrome coronavirus infection . 1393 Proc . Natl . Acad . Sci . U . S . A . 102 , 12543 - 12547 . 1394 Menachery , V . D . , Dinnon , K . H . , 3rd , Yount , B . L . , Jr . , McAnarney , E . T . , Gralinski , L . E . , 1395 Hale , A . , Graham , R . L . , Scobey , T . , Anthony , S . J . , Wang , L . , et al . ( 2020 ) . Trypsin 1396 treatment unlocks barrier for zoonotic bat coronavirus infection . J . Virol . 94 . 1397 Menachery , V . D . , Eisfeld , A . J . , Schafer , A . , Josset , L . , Sims , A . C . , Proll , S . , Fan , S . , Li , 1398 C . , Neumann , G . , Tilton , S . C . , et al . ( 2014 ) . Pathogenic influenza viruses and 1399 coronaviruses utilize similar and contrasting approaches to control interferon - stimulated 1400 gene responses . mBio 5 , e01174 - 01114 . 1401 60 Menachery , V . D . , Yount , B . L . , Jr . , Debbink , K . , Agnihothram , S . , Gralinski , L . E . , Plante , 1402 J . A . , Graham , R . L . , Scobey , T . , Ge , X . Y . , Donaldson , E . F . , et al . ( 2015 ) . A SARS - like 1403 cluster of circulating bat coronaviruses shows potential for human emergence . Nat . Med . 1404 21 , 1508 - 1513 . 1405 Millet , J . K . , and Whittaker , G . R . ( 2014 ) . Host cell entry of Middle East respiratory 1406 syndrome coronavirus after two - step , furin - mediated activation of the spike protein . Proc . 1407 Natl . Acad . Sci . U . S . A . 111 , 15214 - 15219 . 1408 Morawska , L . , and Cao , J . ( 2020 ) . Airborne transmission of SARS - CoV - 2 : the world 1409 should face the reality . Environ . Int . 139 , 105730 . 1410 Mossel , E . C . , Wang , J . , Jeffers , S . , Edeen , K . E . , Wang , S . , Cosgrove , G . P . , Funk , C . J . , 1411 Manzer , R . , Miura , T . A . , Pearson , L . D . , et al . ( 2008 ) . SARS - CoV replicates in primary 1412 human alveolar type II cell cultures but not in type I - like cells . Virology 372 , 127 - 135 . 1413 Odani , K . , Tachibana , M . , Tamashima , R . , and Tsutsumi , Y . ( 2019 ) . Herpes simplex 1414 virus pneumonia : importance of aspiration etiology . Case Rep . Pathol . 2019 , 7623576 . 1415 Okuda , K . , Chen , G . , Subramani , D . B . , Wolf , M . , Gilmore , R . C . , Kato , T . , Radicioni , G . , 1416 Kesimer , M . , Chua , M . , Dang , H . , et al . ( 2019 ) . Localization of secretory mucins 1417 MUC5AC and MUC5B in normal / healthy human airways . Am J . Respir . Crit . Care Med . 1418 199 , 715 - 727 . 1419 Ota , C . , Ng - Blichfeldt , J . P . , Korfei , M . , Alsafadi , H . N . , Lehmann , M . , Skronska - Wasek , 1420 W . , M , M . D . S . , Guenther , A . , Wagner , D . E . , and Konigshoff , M . ( 2018 ) . Dynamic 1421 expression of HOPX in alveolar epithelial cells reflects injury and repair during the 1422 progression of pulmonary fibrosis . Sci Rep 8 , 12983 . 1423 Pan , X . , Chen , D . , Xia , Y . , Wu , X . , Li , T . , Ou , X . , Zhou , L . , and Liu , J . ( 2020a ) . 1424 Asymptomatic cases in a family cluster with SARS - CoV - 2 infection . Lancet Infect . Dis . 1425 20 , 410 - 411 . 1426 Pan , Y . , Zhang , D . , Yang , P . , Poon , L . L . M . , and Wang , Q . ( 2020b ) . Viral load of SARS - 1427 CoV - 2 in clinical samples . Lancet Infect . Dis . 20 , 411 - 412 . 1428 Pandya , V . K . , and Tiwari , R . S . ( 2006 ) . Nasal mucociliary clearance in health and 1429 disease . Indian J . Otolaryngol . Head Neck Surg . 58 , 332 - 334 . 1430 Papineni , R . S . , and Rosenthal , F . S . ( 1997 ) . The size distribution of droplets in the 1431 exhaled breath of healthy human subjects . J . Aerosol Med . 10 , 105 - 116 . 1432 Phillips , L . K . , Deane , A . M . , Jones , K . L . , Rayner , C . K . , and Horowitz , M . ( 2015 ) . Gastric 1433 emptying and glycaemia in health and diabetes mellitus . Nat . Rev . Endocrinol . 11 , 112 - 1434 128 . 1435 61 Quirouette , C . , Younis , N . P . , Reddy , M . B . , and Beauchemin , C . A . A . ( 2020 ) . A 1436 mathematical model describing the localization and spread of influenza A virus infection 1437 within the human respiratory tract . PLoS Comput . Biol . 16 , e1007705 . 1438 Richard , M . , van den Brand , J . M . A . , Bestebroer , T . M . , Lexmond , P . , de Meulder , D . , 1439 Fouchier , R . A . M . , Lowen , A . C . , and Herfst , S . ( 2020 ) . Influenza A viruses are 1440 transmitted via the air from the nasal respiratory epithelium of ferrets . Nat . Commun . 11 , 1441 766 . 1442 Rockx , B . , Kuiken , T . , Herfst , S . , Bestebroer , T . , Lamers , M . M . , Oude Munnink , B . B . , de 1443 Meulder , D . , van Amerongen , G . , van den Brand , J . , Okba , N . M . A . , et al . ( 2020 ) . 1444 Comparative pathogenesis of COVID - 19 , MERS , and SARS in a nonhuman primate 1445 model . Science , http : / / dx . doi . org / 10 . 1126 / science . abb7314 . 1446 Rogers , A . J . , Solus , J . F . , Hunninghake , G . M . , Baron , R . M . , Meyer , N . J . , Janz , D . R . , 1447 Schwartz , D . A . , May , A . K . , Lawson , W . E . , Blackwell , T . S . , et al . ( 2018 ) . MUC5B 1448 promoter polymorphism and development of acute respiratory distress syndrome . Am J . 1449 Respir . Crit . Care Med . 198 , 1342 - 1345 . 1450 Sajuthi , S . P . , DeFord , P . , Jackson , N . D . , Montgomery , M . T . , Everman , J . L . , Rios , C . L . , 1451 Pruesse , E . , Nolin , J . D . , Plender , E . G . , Wechsler , M . E . , et al . ( 2020 ) . Type 2 and 1452 interferon inflammation strongly regulate SARS - CoV - 2 related gene expression in the 1453 airway epithelium . bioRxiv , http : / / dx . doi . org / 10 . 1101 / 2020 . 04 . 09 . 034454 . 1454 Santarpia , J . L . , Rivera , D . N . , Herrera , V . , Morwitzer , M . J . , Creager , H . , Santarpia , G . W . , 1455 Crown , K . K . , Brett - Major , D . , Schnaubelt , E . , Broadhurst , M . J . , et al . ( 2020 ) . 1456 Transmission potential of SARS - CoV - 2 in viral shedding observed at the University of 1457 Nebraska Medical Center . medRxiv , http : / / dx . doi . org / 10 . 1101 / 2020 . 03 . 23 . 20039446 . 1458 Schindelin , J . , Arganda - Carreras , I . , Frise , E . , Kaynig , V . , Longair , M . , Pietzsch , T . , 1459 Preibisch , S . , Rueden , C . , Saalfeld , S . , Schmid , B . , et al . ( 2012 ) . Fiji : an open - source 1460 platform for biological - image analysis . Nat . Methods 9 , 676 - 682 . 1461 Scobey , T . , Yount , B . L . , Sims , A . C . , Donaldson , E . F . , Agnihothram , S . S . , Menachery , 1462 V . D . , Graham , R . L . , Swanstrom , J . , Bove , P . F . , Kim , J . D . , et al . ( 2013 ) . Reverse 1463 genetics with a full - length infectious cDNA of the Middle East respiratory syndrome 1464 coronavirus . Proc . Natl . Acad . Sci . U . S . A . 110 , 16157 - 16162 . 1465 Shang , J . , Ye , G . , Shi , K . , Wan , Y . , Luo , C . , Aihara , H . , Geng , Q . , Auerbach , A . , and Li , 1466 F . ( 2020 ) . Structural basis of receptor recognition by SARS - CoV - 2 . Nature , 1467 http : / / dx . doi . org / 10 . 1038 / s41586 - 020 - 2179 - y . 1468 Sims , A . C . , Baric , R . S . , Yount , B . , Burkett , S . E . , Collins , P . L . , and Pickles , R . J . ( 2005 ) . 1469 Severe acute respiratory syndrome coronavirus infection of human ciliated airway 1470 epithelia : role of ciliated cells in viral spread in the conducting airways of the lungs . J . 1471 Virol . 79 , 15511 - 15524 . 1472 62 Sodhi , C . P . , Nguyen , J . , Yamaguchi , Y . , Werts , A . D . , Lu , P . , Ladd , M . R . , Fulton , W . B . , 1473 Kovler , M . L . , Wang , S . , Prindle , T . , Jr . , et al . ( 2019 ) . A dynamic variation of pulmonary 1474 ACE2 is required to modulate neutrophilic inflammation in response to Pseudomonas 1475 aeruginosa lung infection in mice . J . Immunol . 203 , 3000 - 3012 . 1476 Speen , A . M . , Hoffman , J . R . , Kim , H . H . , Escobar , Y . N . , Nipp , G . E . , Rebuli , M . E . , Porter , 1477 N . A . , and Jaspers , I . ( 2019 ) . Small molecule antipsychotic aripiprazole potentiates 1478 ozone - induced inflammation in airway epithelium . Chem . Res . Toxicol . 32 , 1997 - 2005 . 1479 Sungnak , W . , Huang , N . , Becavin , C . , Berg , M . , Queen , R . , Litvinukova , M . , Talavera - 1480 Lopez , C . , Maatz , H . , Reichart , D . , Sampaziotis , F . , et al . ( 2020 ) . SARS - CoV - 2 entry 1481 factors are highly expressed in nasal epithelial cells together with innate immune genes . 1482 Nat . Med . , http : / / dx . doi . org / 10 . 1038 / s41591 - 020 - 0868 - 6 . 1483 Teunis , P . F . , Brienen , N . , and Kretzschmar , M . E . ( 2010 ) . High infectivity and 1484 pathogenicity of influenza A virus via aerosol and droplet transmission . Epidemics 2 , 1485 215 - 222 . 1486 Thao , T . T . N . , Labroussaa , F . , Ebert , N . , V ' Kovski , P . , Stalder , H . , Portmann , J . , Kelly , J . , 1487 Steiner , S . , Holwerda , M . , Kratzel , A . , et al . ( 2020 ) . Rapid reconstruction of SARS - CoV - 1488 2 using a synthetic genomics platform . Nature , http : / / dx . doi . org / 10 . 1038 / s41586 - 020 - 1489 2294 - 9 . 1490 Thornton , D . J . , Gray , T . , Nettesheim , P . , Howard , M . , Koo , J . S . , and Sheehan , J . K . 1491 ( 2000 ) . Characterization of mucins from cultured normal human tracheobronchial 1492 epithelial cells . Am . J . Physiol . Lung Cell . Mol . Physiol . 278 , L1118 - 1128 . 1493 Tian , X . , Li , C . , Huang , A . , Xia , S . , Lu , S . , Shi , Z . , Lu , L . , Jiang , S . , Yang , Z . , Wu , Y . , et 1494 al . ( 2020 ) . Potent binding of 2019 novel coronavirus spike protein by a SARS 1495 coronavirus - specific human monoclonal antibody . Emerg . Microbes Infect . 9 , 382 - 385 . 1496 Walls , A . C . , Park , Y . J . , Tortorici , M . A . , Wall , A . , McGuire , A . T . , and Veesler , D . ( 2020 ) . 1497 Structure , function , and antigenicity of the SARS - CoV - 2 spike glycoprotein . Cell 181 , 1498 281 - 292 . e286 . 1499 Wang , N . , Rosen , O . , Wang , L . , Turner , H . L . , Stevens , L . J . , Corbett , K . S . , Bowman , 1500 C . A . , Pallesen , J . , Shi , W . , Zhang , Y . , et al . ( 2019 ) . Structural definition of a 1501 neutralization - sensitive epitope on the MERS - CoV S1 - NTD . Cell Rep . 28 , 3395 - 1502 3405 . e3396 . 1503 Wicht , O . , Li , W . , Willems , L . , Meuleman , T . J . , Wubbolts , R . W . , van Kuppeveld , F . J . , 1504 Rottier , P . J . , and Bosch , B . J . ( 2014 ) . Proteolytic activation of the porcine epidemic 1505 diarrhea coronavirus spike fusion protein by trypsin in cell culture . J . Virol . 88 , 7952 - 1506 7961 . 1507 Wilson , N . M . , Norton , A . , Young , F . P . , and Collins , D . W . ( 2020 ) . Airborne transmission 1508 of severe acute respiratory syndrome coronavirus - 2 to healthcare workers : a narrative 1509 review . Anaesthesia , http : / / dx . doi . org / 10 . 1111 / anae . 15093 . 1510 63 Wölfel , R . , Corman , V . M . , Guggemos , W . , Seilmaier , M . , Zange , S . , Muller , M . A . , 1511 Niemeyer , D . , Jones , T . C . , Vollmar , P . , Rothe , C . , et al . ( 2020 ) . Virological assessment 1512 of hospitalized patients with COVID - 2019 . Nature , http : / / dx . doi . org / 10 . 1038 / s41586 - 1513 020 - 2196 - x . 1514 Wrapp , D . , Wang , N . , Corbett , K . S . , Goldsmith , J . A . , Hsieh , C . L . , Abiona , O . , Graham , 1515 B . S . , and McLellan , J . S . ( 2020 ) . Cryo - EM structure of the 2019 - nCoV spike in the 1516 prefusion conformation . Science 367 , 1260 - 1263 . 1517 Wu , A . , Peng , Y . , Huang , B . , Ding , X . , Wang , X . , Niu , P . , Meng , J . , Zhu , Z . , Zhang , Z . , 1518 Wang , J . , et al . ( 2020a ) . Genome composition and divergence of the novel coronavirus 1519 ( 2019 - nCoV ) originating in China . Cell Host Microbe 27 , 325 - 328 . 1520 Wu , X . , Nethery , R . C . , Sabath , B . M . , Braun , D . , and Dominici , F . ( 2020b ) . Exposure to 1521 air pollution and COVID - 19 mortality in the United States . medRxiv , 1522 http : / / dx . doi . org / 10 . 1101 / 2020 . 04 . 05 . 20054502 . 1523 Wu , Z . , and McGoogan , J . M . ( 2020 ) . Characteristics of and important lessons from the 1524 coronavirus disease 2019 ( COVID - 19 ) outbreak in China : summary of a report of 72314 1525 cases from the Chinese Center for Disease Control and Prevention . JAMA , 1526 http : / / dx . doi . org / 10 . 1001 / jama . 2020 . 2648 . 1527 Xie , X . , Muruato , A . , Lokugamage , K . G . , Narayanan , K . , Zhang , X . , Zou , J . , Liu , J . , 1528 Schindewolf , C . , Bopp , N . E . , Aguilar , P . V . , et al . ( 2020 ) . An infectious cDNA clone of 1529 SARS - CoV - 2 . Cell Host Microbe , http : / / dx . doi . org / 10 . 1016 / j . chom . 2020 . 04 . 004 . 1530 Xu , X . , Yu , C . , Qu , J . , Zhang , L . , Jiang , S . , Huang , D . , Chen , B . , Zhang , Z . , Guan , W . , 1531 Ling , Z . , et al . ( 2020 ) . Imaging and clinical features of patients with 2019 novel 1532 coronavirus SARS - CoV - 2 . Eur . J . Nucl . Med . Mol . Imaging 47 , 1275 - 1280 . 1533 Yan , R . , Zhang , Y . , Li , Y . , Xia , L . , Guo , Y . , and Zhou , Q . ( 2020 ) . Structural basis for the 1534 recognition of SARS - CoV - 2 by full - length human ACE2 . Science 367 , 1444 - 1448 . 1535 Ying , T . , Prabakaran , P . , Du , L . , Shi , W . , Feng , Y . , Wang , Y . , Wang , L . , Li , W . , Jiang , S . , 1536 Dimitrov , D . S . , et al . ( 2015 ) . Junctional and allele - specific residues are critical for 1537 MERS - CoV neutralization by an exceptionally potent germline - like antibody . Nat . 1538 Commun . 6 , 8223 . 1539 Yount , B . , Curtis , K . M . , and Baric , R . S . ( 2000 ) . Strategy for systematic assembly of 1540 large RNA and DNA genomes : transmissible gastroenteritis virus model . J . Virol . 74 , 1541 10600 - 10611 . 1542 Yount , B . , Curtis , K . M . , Fritz , E . A . , Hensley , L . E . , Jahrling , P . B . , Prentice , E . , Denison , 1543 M . R . , Geisbert , T . W . , and Baric , R . S . ( 2003 ) . Reverse genetics with a full - length 1544 infectious cDNA of severe acute respiratory syndrome coronavirus . Proc . Natl . Acad . 1545 Sci . U . S . A . 100 , 12995 - 13000 . 1546 64 Yu , X . , Zhang , S . , Jiang , L . , Cui , Y . , Li , D . , Wang , D . , Wang , N . , Fu , L . , Shi , X . , Li , Z . , et 1547 al . ( 2015 ) . Structural basis for the neutralization of MERS - CoV by a human monoclonal 1548 antibody MERS - 27 . Sci . Rep . 5 , 13133 . 1549 Zhu , N . , Zhang , D . , Wang , W . , Li , X . , Yang , B . , Song , J . , Zhao , X . , Huang , B . , Shi , W . , 1550 Lu , R . , et al . ( 2020 ) . A novel coronavirus from patients with pneumonia in China , 2019 . 1551 N . Engl . J . Med . 382 , 727 - 733 . 1552 Zhu , Z . , Chakraborti , S . , He , Y . , Roberts , A . , Sheahan , T . , Xiao , X . , Hensley , L . E . , 1553 Prabakaran , P . , Rockx , B . , Sidorov , I . A . , et al . ( 2007 ) . Potent cross - reactive 1554 neutralization of SARS coronavirus isolates by human monoclonal antibodies . Proc . 1555 Natl . Acad . Sci . U . S . A . 104 , 12123 - 12128 . 1556 Zou , L . , Ruan , F . , Huang , M . , Liang , L . , Huang , H . , Hong , Z . , Yu , J . , Kang , M . , Song , Y . , 1557 Xia , J . , et al . ( 2020 ) . SARS - CoV - 2 viral load in upper respiratory specimens of infected 1558 patients . N . Engl . J . Med . 382 , 1177 - 1179 . 1559 1560 Highlights : 1 . A SARS - CoV - 2 infectious cDNA clone and reporter viruses are generated . 2 . SARS - CoV - 2 and SARS - CoV neutralization assays shows limited cross neutralization . 3 . SARS - CoV - 2 shows a gradient infectivity from the proximal to distal respiratory tract . 4 . Ciliated airway cells and AT - 2 cells are primary targets for SARS - CoV - 2 infection . In Brief Hou et al . present a reverse genetics system for SARS - CoV - 2 , which is then used to make reporter viruses to quantify the ability of patient sera and antibodies to neutralize infectious virus and to examine viral tropism along the human respiratory tract . SacI A B C D F G ORF1a ORF1b S M 8 5’ 3’ 3a E E 7a T7 BsaI BsaI BsaI BsaI / BsmBI BsmBI TTAAATCGGAGCCTACTTGA CCAGGTTAAAATTTCACGTG CTAGATCCACGGTGTTGAAC CATGTAGTGTCACAGGGCCC AGACTTAAAT GGTCCATCTG CTTCACATGT AATTTAGAAG 10 6 GFP - nLuc N ORF1a ORF1b S M 8 5’ 3’ 3a E 10 6 N BsmBI / BsaI ORF1a ORF1b S M 8 5’ 3’ 3a E 10 6 N GFP Fragments icSARS - CoV - 2 - WT icSARS - CoV - 2 - GFP icSARS - CoV - 2 - nLuc - GFP I s o l a t e W T G F P nLu c - G F P Isolate WT GFP nLuc - GFP nLuc - GFP GFP WT mock A B D E * 2 kb 1 . 5 kb 1 kb 0 . 5 kb nLuc - GFP GFP WT C I s o l a t e W T G F P nLu c - G F P geno m e s g RN A 2 s g RN A 3 s g RN A 4 / 5 s g RN A 6 s g RN A 7 s g RN A 8 s g RN A 9 s g RN A 10 F (cid:8) (cid:14) (cid:9)(cid:10) (cid:9)(cid:16) (cid:10)(cid:12) (cid:11)(cid:8) (cid:11)(cid:14) (cid:12)(cid:10) (cid:12)(cid:16) (cid:9)(cid:8) (cid:8) (cid:9)(cid:8) (cid:9) (cid:9)(cid:8) (cid:10) (cid:9)(cid:8) (cid:11) (cid:9)(cid:8) (cid:12) (cid:9)(cid:8) (cid:13) (cid:9)(cid:8) (cid:14) (cid:9)(cid:8) (cid:15) (cid:28)(cid:36)(cid:37)(cid:33)(cid:1)(cid:40)(cid:39)(cid:42)(cid:43)(cid:5)(cid:36)(cid:38)(cid:34)(cid:33)(cid:32)(cid:43)(cid:36)(cid:39)(cid:38)(cid:1)(cid:2)(cid:35)(cid:3) (cid:28) (cid:36) (cid:43) (cid:33) (cid:41) (cid:1)(cid:36) (cid:38) (cid:1) (cid:42) (cid:44)(cid:40) (cid:33) (cid:41) (cid:38) (cid:31) (cid:43) (cid:31) (cid:38) (cid:43) (cid:1) (cid:2) (cid:25) (cid:20) (cid:29) (cid:7) (cid:37) (cid:22) (cid:3) (cid:27)(cid:18)(cid:26)(cid:27)(cid:5)(cid:19)(cid:39)(cid:30)(cid:5)(cid:10)(cid:4)(cid:1)(cid:23)(cid:24)(cid:21)(cid:17)(cid:8)(cid:6)(cid:8)(cid:13) (cid:4)(cid:16)(cid:15)(cid:13)(cid:9)(cid:17)(cid:11) (cid:8)(cid:7) (cid:3)(cid:2)(cid:6) (cid:14)(cid:5)(cid:18)(cid:10)(cid:1)(cid:3)(cid:2)(cid:6) (cid:7) (cid:13) (cid:8)(cid:9) (cid:8)(cid:15) (cid:9)(cid:11) (cid:10)(cid:7) (cid:10)(cid:13) (cid:11)(cid:9) (cid:11)(cid:15) (cid:8)(cid:7) (cid:7) (cid:8)(cid:7) (cid:8) (cid:8)(cid:7) (cid:9) (cid:8)(cid:7) (cid:10) (cid:8)(cid:7) (cid:11) (cid:8)(cid:7) (cid:12) (cid:8)(cid:7) (cid:13) (cid:8)(cid:7) (cid:14) (cid:27)(cid:35)(cid:36)(cid:32)(cid:1)(cid:39)(cid:38)(cid:41)(cid:42)(cid:5)(cid:35)(cid:37)(cid:33)(cid:32)(cid:31)(cid:42)(cid:35)(cid:38)(cid:37)(cid:1)(cid:2)(cid:34)(cid:3) (cid:27) (cid:35) (cid:42) (cid:32) (cid:40) (cid:1)(cid:35) (cid:37) (cid:1) (cid:41) (cid:43)(cid:39) (cid:32) (cid:40) (cid:37) (cid:30) (cid:42) (cid:30) (cid:37) (cid:42) (cid:1) (cid:2) (cid:24) (cid:19) (cid:28) (cid:6) (cid:36) (cid:21) (cid:3) (cid:26)(cid:17)(cid:25)(cid:26)(cid:5)(cid:18)(cid:38)(cid:29)(cid:5)(cid:9)(cid:4)(cid:1)(cid:22)(cid:23)(cid:20)(cid:16)(cid:12) (cid:4)(cid:16)(cid:15)(cid:13)(cid:9)(cid:17)(cid:11) (cid:8)(cid:7) (cid:3)(cid:2)(cid:6) (cid:14)(cid:5)(cid:18)(cid:10)(cid:1)(cid:3)(cid:2)(cid:6) (cid:9)(cid:11)(cid:34) (cid:11)(cid:15)(cid:34) (cid:14)(cid:9)(cid:34) (cid:8)(cid:7) (cid:7) (cid:8)(cid:7) (cid:8) (cid:8)(cid:7) (cid:9) (cid:8)(cid:7) (cid:10) (cid:8)(cid:7) (cid:11) (cid:8)(cid:7) (cid:12) (cid:8)(cid:7) (cid:13) (cid:8)(cid:7) (cid:14) (cid:28) (cid:35) (cid:42) (cid:33) (cid:40) (cid:1)(cid:35) (cid:37) (cid:1) (cid:41) (cid:43)(cid:39) (cid:33) (cid:40) (cid:37) (cid:31) (cid:42) (cid:31) (cid:37) (cid:42) (cid:1) (cid:2) (cid:25) (cid:19) (cid:29) (cid:6) (cid:36) (cid:22) (cid:3) (cid:35)(cid:32)(cid:27)(cid:17)(cid:26)(cid:27)(cid:4)(cid:18)(cid:38)(cid:30)(cid:4)(cid:9)(cid:4)(cid:20)(cid:19)(cid:25)(cid:1)(cid:2)(cid:23)(cid:24)(cid:21)(cid:1)(cid:16)(cid:1)(cid:7)(cid:5)(cid:7)(cid:10)(cid:3) (cid:12)(cid:13)(cid:18)(cid:17) (cid:12)(cid:13)(cid:18)(cid:17)(cid:1)(cid:14)(cid:19)(cid:18)(cid:15)(cid:16) (cid:11)(cid:10)(cid:3)(cid:2)(cid:3)(cid:4)(cid:9)(cid:6) (cid:11)(cid:10)(cid:3)(cid:2)(cid:9)(cid:5)(cid:8)(cid:7)(cid:11)(cid:10)(cid:3)(cid:2)(cid:4)(cid:5)(cid:6)(cid:6) 0 μ g / mL 1 μ g / mL 5 μ g / mL 24h 48h Vero Vero - Furin 24h 48h 72h Vero , MOI = 0 . 03 trypsin : A C 24h 48h 72h 96h LLC - MK LLC - MK - TMPRSS2 E MOI = 0 . 03 MOI = 0 . 03 (cid:9)(cid:11)(cid:34) (cid:11)(cid:15)(cid:34) (cid:14)(cid:9)(cid:34) (cid:8)(cid:7) (cid:7) (cid:8)(cid:7) (cid:8) (cid:8)(cid:7) (cid:9) (cid:8)(cid:7) (cid:10) (cid:8)(cid:7) (cid:11) (cid:8)(cid:7) (cid:12) (cid:8)(cid:7) (cid:13) (cid:28) (cid:35) (cid:42) (cid:33) (cid:40) (cid:1)(cid:35) (cid:37) (cid:1) (cid:41) (cid:43)(cid:39) (cid:33) (cid:40) (cid:37) (cid:31) (cid:42) (cid:31) (cid:37) (cid:42) (cid:1) (cid:2) (cid:25) (cid:19) (cid:29) (cid:6) (cid:36) (cid:22) (cid:3) (cid:35)(cid:32)(cid:27)(cid:17)(cid:26)(cid:27)(cid:4)(cid:18)(cid:38)(cid:30)(cid:4)(cid:9)(cid:4)(cid:20)(cid:19)(cid:25)(cid:1)(cid:2)(cid:23)(cid:24)(cid:21)(cid:1)(cid:16)(cid:1)(cid:7)(cid:5)(cid:7)(cid:10)(cid:3) (cid:11)(cid:11)(cid:9)(cid:1)(cid:12)(cid:10) (cid:11)(cid:11)(cid:9)(cid:1)(cid:12)(cid:10)(cid:1)(cid:16)(cid:12)(cid:13)(cid:14)(cid:15)(cid:15)(cid:5) (cid:13)(cid:8)(cid:3)(cid:2)(cid:3)(cid:3)(cid:5)(cid:7) (cid:13)(cid:8)(cid:3)(cid:2)(cid:4)(cid:3)(cid:7)(cid:6) (cid:13)(cid:8)(cid:3)(cid:2)(cid:3)(cid:3)(cid:7)(cid:3) B D G F H (cid:8)(cid:10)(cid:30) (cid:10)(cid:14)(cid:30) (cid:7)(cid:6) (cid:6) (cid:7)(cid:6) (cid:7) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:22) (cid:31) (cid:39) (cid:28) (cid:37) (cid:1)(cid:31) (cid:34) (cid:1) (cid:38) (cid:40)(cid:36) (cid:28) (cid:37) (cid:34) (cid:25) (cid:39) (cid:25) (cid:34) (cid:39) (cid:1) (cid:2) (cid:21) (cid:16) (cid:23) (cid:5) (cid:33) (cid:18) (cid:3) (cid:22)(cid:37)(cid:41)(cid:36)(cid:38)(cid:31)(cid:34)(cid:1)(cid:31)(cid:34)(cid:1)(cid:31)(cid:34)(cid:29)(cid:28)(cid:26)(cid:39)(cid:28)(cid:27)(cid:1)(cid:24)(cid:28)(cid:37)(cid:35)(cid:1)(cid:26)(cid:28)(cid:32)(cid:32)(cid:38)(cid:1) (cid:4)(cid:1)(cid:19)(cid:15)(cid:3)(cid:17)(cid:13) (cid:5)(cid:1)(cid:19)(cid:15)(cid:3)(cid:17)(cid:13) (cid:8)(cid:1)(cid:19)(cid:15)(cid:3)(cid:17)(cid:13) (cid:2)(cid:19)(cid:20)(cid:17)(cid:1)(cid:15)(cid:1)(cid:6)(cid:4)(cid:6)(cid:9)(cid:3) (cid:14)(cid:12)(cid:4)(cid:2)(cid:4)(cid:6)(cid:11)(cid:9) (cid:14)(cid:12)(cid:4)(cid:2)(cid:4)(cid:5)(cid:11)(cid:7) (cid:14)(cid:12)(cid:4)(cid:2)(cid:4)(cid:10)(cid:4)(cid:10) (cid:14)(cid:12)(cid:4)(cid:2)(cid:4)(cid:4)(cid:5)(cid:6) - 3 - 2 - 1 0 1 2 0 50 100 ( Log 10 µ g / ml ) % N e u t r a li z a t i on icMERS - CoV - nLuc MERS - 27 m336 EDE1 - C10 - 3 - 2 - 1 0 1 2 0 50 100 ( Log 10 µ g / ml ) % N e u t r a li z a t i on icSARS - CoV - nLuc S230 S230 . 15 S227 . 9 MERS - 27 m336 EDE1 - C10 - 3 - 2 - 1 0 1 2 0 50 100 ( Log 10 µ g / ml ) % N e u t r a li z a t i on icSARS - CoV - 2 - nLuc - GFP S230 S230 . 15 S227 . 9 MERS - 27 m336 EDE1 - C10 0 2 4 6 0 50 100 ( Log 10 diution ) % N e u t r a li z a t i on icSARS - CoV - 2 - nLuc - GFP Pre - boost mouse serum Post - boost mouse serum 0 2 4 6 0 50 100 ( Log 10 dilution ) % N e u t r a li z a t i on icMERS - CoV - nLuc COVID - 19 human sera 1 to 10 0 2 4 6 0 50 100 ( Log 10 diution ) % N e u t r a li z a t i on icSARS - CoV - nLuc SARS human serum A SARS human serum B SARS human serum C SARS human serum D SARS human serum E COVID - 19 human sera 1 to 10 0 2 4 6 0 50 100 ( Log 10 diution ) % N e u t r a li z a t i on icSARS - CoV - 2 - nLuc - GFP SARS human serum A SARS human serum B SARS human serum C SARS human serum D SARS human serum E COVID - 19 human sera 1 to 10 SARS - CoV SARS - CoV - 2 0 20 40 60 80 200400600800 I D 50 SARS human sera COVID - 19 human sera Cross - neutralization A B C D E F G H Nasal Tissue Bronchial Tissue 0 . 0 0 . 3 0 . 6 0 . 9 1 . 2 1 . 5 1 . 8 R e l a t i v e e x p r e ss i on no r m a li z ed t o T BP P = 0 . 641 Nasal Tissue Bronchial Tissue 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 2 . 5 3 . 0 R e l a t i v e e x p r e ss i on no r m a li z ed t o T BP P = 0 . 016 T r a c hea B r on c h i B r on c h i o l e s A l v eo li 0 1 2 3 4 5 R e l a t i v e e x p r e ss i on n o r m a li z ed t o G AP DH P = 0 . 851 T r a c h ea B r o n c h i B r o n c h i o l e s A l v e o li 0 . 0 0 . 5 1 . 0 1 . 5 R e l a t i v e e x p r e ss i on no r m a li z ed t o G AP DH P = 0 . 021 0 10 20 30 40 50 P r opo r t i on o f A C E 2 + c e ll s a m ong m a r k e r + c e ll s ( % ) FOXJ1 MUC5B Bronchi FOXJ1 MUC5B Nose P < 0 . 001 P < 0 . 001 P = 0 . 005 Nose Bronchi 0 10 20 30 40 P r opo r t i on o f A C E 2 + c e ll s ( % ) 0 1 2 3 4 5 6 7 8 9 0 5 10 15 20 6080100 # of ACE2 + dots P r opo r t i on o f A C E 2 + c e ll s ( % ) ACE2 ( Bronchi ) FOXJ1 MUC5B P < 0 . 001 N a s a l T r a c hea l I n t e r m ed i a t e D i s t a l 0 1 2 3 4 P r opo r t i on o f A C E 2 + c e ll s ( % ) ACE2 N a s a l T r a c hea l I n t e r m ed i a t e D i s t a l 0 5 10 15 20 25 TMPRSS2 P r opo r t i on o f T M P R SS 2 + c e ll s ( % ) ACE2 TMPRSS2 ACE2 TMPRSS2 Nasal epithelium Trachea Bronchiole Alveoli A B C ACE2 TMPRSS2 ACE2 TMPRSS2 D Nasal epithelium E ACE2 ( Nose ) ACE2 ( Bronchi ) G H 0 1 2 3 4 5 6 7 8 9 0 5 10 15 20 60 80100 # of ACE2 + dots P r opo r t i on o f A C E 2 + c e ll s ( % ) ACE2 ( Nasal ) FOXJ1 MUC5B P < 0 . 001 F I ACE2 FOXJ1 ACE2 MUC5B ACE2FOXJ1 ACE2 MUC5B Bronchi Alveoli ACE2FOXJ1 ACE2 ACE2 ACE2SFTPC HOPXACE2 i ii iii iv v vi vii (cid:10) (cid:19)(cid:18)(cid:19) (cid:20) (cid:1) (cid:4) (cid:10) (cid:19)(cid:18)(cid:19) (cid:20) (cid:1) (cid:5) (cid:10) (cid:19)(cid:18)(cid:19) (cid:20) (cid:1) (cid:6) (cid:10) (cid:19)(cid:18)(cid:19) (cid:20) (cid:1) (cid:7) (cid:10) (cid:19)(cid:18)(cid:19) (cid:20) (cid:1) (cid:8) (cid:3) (cid:5)(cid:3) (cid:7)(cid:3) (cid:9)(cid:3) (cid:2) (cid:1) (cid:12) (cid:16)(cid:17)(cid:16) (cid:11) (cid:22) (cid:14) (cid:13) (cid:1) (cid:21) (cid:23) (cid:20) (cid:15) (cid:11)(cid:12)(cid:14) (cid:6) (cid:8)(cid:10) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:20)(cid:35)(cid:40)(cid:37)(cid:38)(cid:1)(cid:36)(cid:35)(cid:38)(cid:39)(cid:4)(cid:31)(cid:34)(cid:30)(cid:29)(cid:27)(cid:39)(cid:31)(cid:35)(cid:34) (cid:25) (cid:31) (cid:37) (cid:26) (cid:32)(cid:1) (cid:39) (cid:31) (cid:39) (cid:29) (cid:37) (cid:1) (cid:2) (cid:1) (cid:22) (cid:19) (cid:24) (cid:5) (cid:33) (cid:21) (cid:3) (cid:23)(cid:17)(cid:18)(cid:1)(cid:2)(cid:34)(cid:1)(cid:16)(cid:1)(cid:9)(cid:1)(cid:28)(cid:35)(cid:34)(cid:35)(cid:37)(cid:38)(cid:3) (cid:6) (cid:8)(cid:10) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:19)(cid:34)(cid:39)(cid:36)(cid:37)(cid:1)(cid:35)(cid:34)(cid:37)(cid:38)(cid:4)(cid:30)(cid:33)(cid:29)(cid:28)(cid:26)(cid:38)(cid:30)(cid:34)(cid:33) (cid:24) (cid:30) (cid:36) (cid:25) (cid:31)(cid:1) (cid:38) (cid:30) (cid:38) (cid:28) (cid:36) (cid:1) (cid:2) (cid:1) (cid:22) (cid:18) (cid:23) (cid:5) (cid:32) (cid:20) (cid:3) (cid:1)(cid:19)(cid:21)(cid:17)(cid:1)(cid:2)(cid:33)(cid:1)(cid:16)(cid:1)(cid:15)(cid:1)(cid:27)(cid:34)(cid:33)(cid:34)(cid:36)(cid:37)(cid:3) icSARS - CoV - 2 - GFP infected LAE at 72hpi Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 HNE LAE SAE AT2 - like AT1 - like (cid:6) (cid:8)(cid:10) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:20)(cid:34)(cid:39)(cid:36)(cid:37)(cid:1)(cid:35)(cid:34)(cid:37)(cid:38)(cid:4)(cid:30)(cid:33)(cid:29)(cid:28)(cid:26)(cid:38)(cid:30)(cid:34)(cid:33) (cid:24) (cid:30) (cid:36) (cid:25) (cid:31)(cid:1) (cid:38) (cid:30) (cid:38) (cid:28) (cid:36) (cid:1) (cid:2) (cid:1) (cid:22) (cid:19) (cid:23) (cid:5) (cid:32) (cid:21) (cid:3) (cid:21)(cid:17)(cid:18)(cid:1)(cid:2)(cid:1)(cid:33)(cid:1)(cid:16)(cid:1)(cid:13)(cid:1)(cid:27)(cid:34)(cid:33)(cid:34)(cid:36)(cid:37)(cid:3) A B i ii iii C D i ii GFP cilia staining (cid:6) (cid:7)(cid:8) (cid:8)(cid:10) (cid:9)(cid:12) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:19)(cid:34)(cid:39)(cid:36)(cid:37)(cid:1)(cid:35)(cid:34)(cid:37)(cid:38)(cid:4)(cid:30)(cid:33)(cid:29)(cid:28)(cid:27)(cid:38)(cid:30)(cid:34)(cid:33) (cid:25) (cid:30) (cid:36) (cid:26) (cid:31)(cid:1) (cid:38) (cid:30) (cid:38) (cid:28) (cid:36) (cid:1) (cid:2) (cid:1) (cid:21) (cid:18) (cid:24) (cid:5) (cid:32) (cid:20) (cid:3) (cid:23)(cid:16)(cid:22)(cid:23)(cid:4)(cid:17)(cid:34)(cid:25)(cid:4)(cid:8)(cid:1)(cid:30)(cid:37)(cid:34)(cid:31)(cid:26)(cid:38)(cid:28) (cid:3)(cid:1)(cid:2) (cid:4)(cid:1)(cid:2) (cid:6) (cid:7)(cid:8) (cid:8)(cid:10) (cid:9)(cid:12) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:20)(cid:35)(cid:40)(cid:37)(cid:38)(cid:1)(cid:36)(cid:35)(cid:38)(cid:39)(cid:4)(cid:31)(cid:34)(cid:30)(cid:29)(cid:28)(cid:39)(cid:31)(cid:35)(cid:34) (cid:26) (cid:31) (cid:37) (cid:27) (cid:32)(cid:1) (cid:39) (cid:31) (cid:39) (cid:29) (cid:37) (cid:1) (cid:2) (cid:1) (cid:22) (cid:18) (cid:25) (cid:5) (cid:33) (cid:21) (cid:3) (cid:31)(cid:28)(cid:24)(cid:16)(cid:23)(cid:24)(cid:4)(cid:17)(cid:35)(cid:26)(cid:4)(cid:8)(cid:4)(cid:19)(cid:18)(cid:22) (cid:3)(cid:1)(cid:2) (cid:4)(cid:1)(cid:2) (cid:6) (cid:7)(cid:8) (cid:8)(cid:10) (cid:9)(cid:12) (cid:10)(cid:14) (cid:13)(cid:8) (cid:15)(cid:12) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:19)(cid:36)(cid:41)(cid:38)(cid:39)(cid:1)(cid:37)(cid:36)(cid:39)(cid:40)(cid:4)(cid:32)(cid:35)(cid:31)(cid:30)(cid:29)(cid:40)(cid:32)(cid:36)(cid:35) (cid:26) (cid:32) (cid:38) (cid:28) (cid:33)(cid:1) (cid:40) (cid:32) (cid:40) (cid:30) (cid:38) (cid:1) (cid:2) (cid:1) (cid:21) (cid:18) (cid:25) (cid:5) (cid:34) (cid:20) (cid:3) (cid:32)(cid:29)(cid:23)(cid:16)(cid:22)(cid:23)(cid:4)(cid:17)(cid:36)(cid:26)(cid:4)(cid:8)(cid:4)(cid:27)(cid:24) (cid:3)(cid:1)(cid:2) (cid:4)(cid:1)(cid:2) E i ii iii (cid:7) (cid:9)(cid:11) (cid:11)(cid:15) (cid:14)(cid:9) (cid:8)(cid:7) (cid:9) (cid:8)(cid:7) (cid:10) (cid:8)(cid:7) (cid:11) (cid:8)(cid:7) (cid:12) (cid:8)(cid:7) (cid:13) (cid:8)(cid:7) (cid:14) (cid:8)(cid:7) (cid:15) (cid:19)(cid:36)(cid:41)(cid:38)(cid:39)(cid:1)(cid:37)(cid:36)(cid:39)(cid:40)(cid:5)(cid:31)(cid:35)(cid:29)(cid:28)(cid:26)(cid:40)(cid:31)(cid:36)(cid:35) (cid:24) (cid:31) (cid:38) (cid:25) (cid:33)(cid:1) (cid:40) (cid:31) (cid:40) (cid:28) (cid:38) (cid:1) (cid:3) (cid:1) (cid:21) (cid:18) (cid:23) (cid:6) (cid:34) (cid:20) (cid:4) (cid:17)(cid:22)(cid:8)(cid:5)(cid:1)(cid:2)(cid:1)(cid:17)(cid:22)(cid:9)(cid:5)(cid:33)(cid:31)(cid:32)(cid:28)(cid:1)(cid:26)(cid:28)(cid:33)(cid:33)(cid:39)(cid:1)(cid:3)(cid:35)(cid:1)(cid:16)(cid:1)(cid:10)(cid:1)(cid:27)(cid:36)(cid:35)(cid:36)(cid:38)(cid:39)(cid:1)(cid:6)(cid:1)(cid:28)(cid:25)(cid:26)(cid:30)(cid:1)(cid:4) iv (cid:9)(cid:11) (cid:11)(cid:15) (cid:14)(cid:9) (cid:16)(cid:13) (cid:8)(cid:7) (cid:9) (cid:8)(cid:7) (cid:10) (cid:8)(cid:7) (cid:11) (cid:8)(cid:7) (cid:12) (cid:8)(cid:7) (cid:13) (cid:8)(cid:7) (cid:14) (cid:8)(cid:7) (cid:15) (cid:22)(cid:37)(cid:42)(cid:39)(cid:40)(cid:1)(cid:38)(cid:37)(cid:40)(cid:41)(cid:4)(cid:33)(cid:36)(cid:32)(cid:31)(cid:29)(cid:41)(cid:33)(cid:37)(cid:36) (cid:27) (cid:33) (cid:39) (cid:28) (cid:34)(cid:1) (cid:41) (cid:33) (cid:41) (cid:31) (cid:39) (cid:1) (cid:2) (cid:1) (cid:25) (cid:21) (cid:26) (cid:6) (cid:35) (cid:23) (cid:3) (cid:3)(cid:5)(cid:2) (cid:4)(cid:1)(cid:2) (cid:25)(cid:1)(cid:17)(cid:1)(cid:7)(cid:5)(cid:7)(cid:9)(cid:13)(cid:9) (cid:25)(cid:1)(cid:17)(cid:1)(cid:7)(cid:5)(cid:7)(cid:11)(cid:12)(cid:13) (cid:25)(cid:1)(cid:17)(cid:1)(cid:7)(cid:5)(cid:12)(cid:12)(cid:16)(cid:15) (cid:25)(cid:1)(cid:17)(cid:7)(cid:5)(cid:7)(cid:7)(cid:8)(cid:15) (cid:19)(cid:37)(cid:35)(cid:38)(cid:28)(cid:39)(cid:33)(cid:40)(cid:37)(cid:36)(cid:1)(cid:37)(cid:32)(cid:1)(cid:41)(cid:33)(cid:41)(cid:31)(cid:39)(cid:40)(cid:1)(cid:33)(cid:36)(cid:1)(cid:22)(cid:24)(cid:20)(cid:1)(cid:28)(cid:36)(cid:30)(cid:1)(cid:23)(cid:18)(cid:20)(cid:1)(cid:29)(cid:42)(cid:34)(cid:41)(cid:42)(cid:39)(cid:31)(cid:40)(cid:1) (cid:22)(cid:24)(cid:20) (cid:23)(cid:18)(cid:20) (cid:26)(cid:18)(cid:20) (cid:18)(cid:27)(cid:8) (cid:18)(cid:27)(cid:7) (cid:7)(cid:6) (cid:6) (cid:7)(cid:6) (cid:7) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:29) (cid:33) (cid:40) (cid:30) (cid:35)(cid:1) (cid:42) (cid:33) (cid:42) (cid:31) (cid:40) (cid:1) (cid:2) (cid:1) (cid:25) (cid:21) (cid:28) (cid:5) (cid:36) (cid:23) (cid:3) (cid:19)(cid:38)(cid:36)(cid:39)(cid:30)(cid:40)(cid:33)(cid:41)(cid:38)(cid:37)(cid:1)(cid:38)(cid:32)(cid:1)(cid:39)(cid:31)(cid:30)(cid:34)(cid:1)(cid:42)(cid:33)(cid:42)(cid:31)(cid:40)(cid:41) (cid:25)(cid:1)(cid:17)(cid:1)(cid:6)(cid:4)(cid:15)(cid:11)(cid:6)(cid:14) (cid:25)(cid:17)(cid:1)(cid:6)(cid:4)(cid:10)(cid:8)(cid:6)(cid:14) (cid:25)(cid:16)(cid:6)(cid:4)(cid:6)(cid:6)(cid:6)(cid:7) (cid:25)(cid:16)(cid:6)(cid:4)(cid:6)(cid:6)(cid:6)(cid:7) v vi icSARS - CoV - 2 - GFP infected HNE icSARS - CoV - 2 - GFP infected LAE W T G F P nLu c - G F P M o ck W T G F P nLu c - G F P M o ck Ladde r sgRNA - 5 ( M ) sgRNA - 9 ( N ) A B 15102 A B C D E F G 3 k b 4 k b 5 k b 6 k b 2 k b 1 . 5 k b 1 k b C SacI 0 μ g / mL 1 μ g / mL 5 μ g / mL Vero , MOI = 0 . 03 trypsin : 24h 48h 24h 48h 72h MOI = 0 . 03 Vero Vero - Furin 24h 48h 72h 96h MOI = 0 . 03 LLC - MK LLC - MK - TMPRSS2 A B C 48h 72h 96h LAE , MOI = 0 . 5 i c SA R S - C o V - 2 - G F P i c S A R S - U r b a n i - G F P 24h A B (cid:6) (cid:7)(cid:8) (cid:8)(cid:10) (cid:9)(cid:12) (cid:10)(cid:14) (cid:12)(cid:6) (cid:13)(cid:8) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:18)(cid:33)(cid:38)(cid:35)(cid:36)(cid:1)(cid:34)(cid:33)(cid:36)(cid:37)(cid:4)(cid:29)(cid:32)(cid:28)(cid:27)(cid:26)(cid:37)(cid:29)(cid:33)(cid:32) (cid:24) (cid:29) (cid:35) (cid:25) (cid:30)(cid:1) (cid:37) (cid:29) (cid:37) (cid:27) (cid:35) (cid:1) (cid:2) (cid:1) (cid:20) (cid:17) (cid:23) (cid:5) (cid:31) (cid:19) (cid:3) (cid:22)(cid:15)(cid:21)(cid:22)(cid:4)(cid:8)(cid:1)(cid:33)(cid:32)(cid:1)(cid:19)(cid:15)(cid:16)(cid:1) (cid:2)(cid:12)(cid:17)(cid:16)(cid:17)(cid:18)(cid:1)(cid:4)(cid:3) (cid:10)(cid:9)(cid:7)(cid:19)(cid:17)(cid:15)(cid:11)(cid:20)(cid:13)(cid:6)(cid:5)(cid:8) (cid:6) (cid:7)(cid:8) (cid:8)(cid:10) (cid:9)(cid:12) (cid:10)(cid:14) (cid:12)(cid:6) (cid:13)(cid:8) (cid:7)(cid:6) (cid:8) (cid:7)(cid:6) (cid:9) (cid:7)(cid:6) (cid:10) (cid:7)(cid:6) (cid:11) (cid:7)(cid:6) (cid:12) (cid:7)(cid:6) (cid:13) (cid:7)(cid:6) (cid:14) (cid:18)(cid:33)(cid:38)(cid:35)(cid:36)(cid:1)(cid:34)(cid:33)(cid:36)(cid:37)(cid:4)(cid:29)(cid:32)(cid:28)(cid:27)(cid:26)(cid:37)(cid:29)(cid:33)(cid:32) (cid:24) (cid:29) (cid:35) (cid:25) (cid:30)(cid:1) (cid:37) (cid:29) (cid:37) (cid:27) (cid:35) (cid:1) (cid:2) (cid:1) (cid:20) (cid:17) (cid:23) (cid:5) (cid:31) (cid:19) (cid:3) (cid:22)(cid:15)(cid:21)(cid:22)(cid:1)(cid:33)(cid:32)(cid:1)(cid:19)(cid:15)(cid:16)(cid:1) (cid:2)(cid:14)(cid:17)(cid:16)(cid:17)(cid:18)(cid:1)(cid:5)(cid:3) (cid:10)(cid:18)(cid:13)(cid:12)(cid:16)(cid:15)(cid:4)(cid:11)(cid:9)(cid:10)(cid:18)(cid:13)(cid:12)(cid:16)(cid:15)(cid:4)(cid:7)(cid:6)(cid:8) C 96h icSARS - 2CoV - GFP infected HNE at 72hpi Donor A Donor B Donor C Donor D Donor E i ii iii D i ii i c SA R S - C o V - 2 - G F P i Table S1 . Demographics of normal subjects studied and experimental use , Related to the STAR Methods # Age Sex Smoking History Airway region Collection Related figure 1 40 M NS Bronchi Bronchial brushing Fig . 4E - I 2 22 M NS Bronchi Bronchial brushing Fig . 4E - I 3 25 M NS Bronchi Bronchial brushing Fig . 4E - I 4 48 M Unknown Nose Excess surgical tissue Fig . 4A 5 58 M Unknown Nose Excess surgical tissue Fig . 4A 6 57 M Unknown Nose Excess surgical tissue Fig . 4E - I 7 41 F Unknown Nose Excess surgical tissue Fig . 4E - I 8 73 F Unknown Nose Excess surgical tissue Fig . 4E - I 9 15 M NS Lung Transplant donor lung Fig . 4Evi , 4Evii 10 25 M NS Lung Transplant donor lung Fig . 4Evi , 4Evii 11 19 M NS Lung Transplant donor lung Fig . 4Evi , 4Evii 12 17 F NS Lung Transplant donor lung Fig . 4A , 5A 13 52 F NS Lung Transplant donor lung Fig . 4A , 5A 14 37 M NS Lung Transplant donor lung Fig . 4A , 5A 15 44 M NS Lung Transplant donor lung Fig . 4A , 5A 16 55 F NS Lung Transplant donor lung Fig . 4A , 4C , 5A 17 27 M NS Lung Transplant donor lung Fig . 4A , 5A 18 35 F 5 cigarettes / month Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 19 22 M NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 20 39 F NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 21 35 M 5 PY Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 22 23 M NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 23 22 F NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 24 22 F NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 25 42 M NS Nose / Bronchi Nasal scrape / Bronchial brushing Fig . 4B 26 35 F NS Lung Transplant donor lung Fig . 4C 27 53 F NS Lung Transplant donor lung Fig . 4C 28 24 M NS Lung Transplant donor lung Fig . 4C 29 25 M NS Lung Transplant donor lung Fig . 4C 30 15 M NS Lung Transplant donor lung Fig . 4C 31 27 M NS Lung Transplant donor lung Fig . 4C 32 39 F Unknown Tonsil Excess surgical tissue Fig . S3 33 37 F Unknown Tonsil Excess surgical tissue Fig . S3 34 38 F Unknown Tonsil Excess surgical tissue Fig . S3 NS = never smoker , PY = pack - year Table S2 . Demographics of CF subjects studied for RNA - ISH experiment , Related to the STAR Methods # Age Sex CFTR mutation Airway region Collection Related figure 1 45 F DF508 / N1303K Lung Lung transplantation Fig . 5A 2 42 F DF508 / DF508 Lung Lung transplantation Fig . 5A 3 30 F DF508 / DF508 Lung Lung transplantation Fig . 5A 4 15 M DF508 / W1282X Lung Lung transplantation Fig . 5A 5 34 M DF508 / W1282X Lung Lung transplantation Fig . 5A 6 59 F DF508 / N1303K Lung Lung transplantation Fig . 5A